BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C; Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91. [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055] [Cited by in Crossref: 597] [Cited by in F6Publishing: 596] [Article Influence: 199.0] [Reference Citation Analysis]
Number Citing Articles
1 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. J Autoimmun 2019;100:17-26. [PMID: 30862450 DOI: 10.1016/j.jaut.2019.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
3 Shen J, Li G, Zhu Y, Xu Q, Zhou H, Xu K, Huang K, Zhan R, Pan J. Foxo1-induced miR-92b down-regulation promotes blood-brain barrier damage after ischaemic stroke by targeting NOX4. J Cell Mol Med 2021;25:5269-82. [PMID: 33955666 DOI: 10.1111/jcmm.16537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs 2021;39:1072-80. [PMID: 33646489 DOI: 10.1007/s10637-021-01090-w] [Reference Citation Analysis]
5 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
6 Giallongo S, Lo Re O, Vinciguerra M. Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers. Cancers (Basel) 2019;11:E676. [PMID: 31096699 DOI: 10.3390/cancers11050676] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Reference Citation Analysis]
8 Chen J, Wang J, Xie F. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis. Medicine (Baltimore) 2021;100:e27013. [PMID: 34559096 DOI: 10.1097/MD.0000000000027013] [Reference Citation Analysis]
9 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Reference Citation Analysis]
10 Zhou Z, Jiang H, Tu K, Yu W, Zhang J, Hu Z, Zhang H, Hao D, Huang P, Wang J, Wang A, Xiao Z, He C. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:18. [PMID: 30646949 DOI: 10.1186/s13046-018-1011-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
11 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lin J, Zhao S, Wang D, Song Y, Che Y, Yang X, Mao J, Xie F, Long J, Bai Y, Yang X, Zhang L, Bian J, Lu X, Sang X, Pan J, Wang K, Zhao H. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Front Immunol 2021;12:673248. [PMID: 34211467 DOI: 10.3389/fimmu.2021.673248] [Reference Citation Analysis]
13 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Li C, He WQ. The impact of universal hepatitis B vaccine on the trend of liver cancer from the Global Burden of Disease Study 2017. Liver Int 2021;41:1762-74. [PMID: 33590659 DOI: 10.1111/liv.14821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 VoPham T. Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. Curr Epidemiol Rep 2019;6:50-66. [PMID: 31080703 DOI: 10.1007/s40471-019-0183-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
16 Ren SS, Xu LL, Wang P, Li L, Hu YT, Xu MQ, Zhang M, Yan LN, Wen TF, Li B, Wang WT, Yang JY. Circadian Rhythms Have Effects on Surgical Outcomes of Liver Transplantation for Patients With Hepatocellular Carcinoma: A Retrospective Analysis of 147 Cases in a Single Center. Transplant Proc 2019;51:1913-9. [PMID: 31399175 DOI: 10.1016/j.transproceed.2019.03.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Zhang L, Wang Z, Li M, Sun P, Bai T, Wang W, Bai H, Gou J, Wang Z. HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells. Front Cell Dev Biol 2021;9:707073. [PMID: 34527669 DOI: 10.3389/fcell.2021.707073] [Reference Citation Analysis]
18 Raoul JL, Faivre S, Frenel JS, Rimassa L. Medical oncologists must get more involved in systemic treatment. Ann Oncol 2019;30:6-8. [PMID: 32081277 DOI: 10.1093/annonc/mdy471] [Reference Citation Analysis]
19 Yu L, Wang F, Tai M, Li J, Gong S, Zhou Z, Yin X, Gu X, Li C. 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway. Eur J Pharmacol 2020;882:173299. [PMID: 32589884 DOI: 10.1016/j.ejphar.2020.173299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
22 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
23 Wei Y, Song Q, Zhang F, Yuan T. Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC. Can J Gastroenterol Hepatol 2021;2021:5601678. [PMID: 34912753 DOI: 10.1155/2021/5601678] [Reference Citation Analysis]
24 Yeung R, Beaton L, Rackley T, Weber B, Hamm J, Lee R, Camborde M, Pearson M, Duzenli C, Loewen S, Liu M, Ma R, Schellenberg D. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas. Clinical Oncology 2019;31:365-73. [DOI: 10.1016/j.clon.2019.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
25 Song SS, Ying JF, Zhang YN, Pan HY, He XL, Hu ZM, Wang HJ, Dou XB, Mou XZ. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:3181-8. [PMID: 32256814 DOI: 10.3892/ol.2020.11430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Gu J, Zhang E, Liang B, Zhang Z, Long X, Xiang S, Wang W, Chen X, Huang Z. Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma. World J Surg 2020;44:2777-83. [PMID: 32322938 DOI: 10.1007/s00268-020-05528-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Reference Citation Analysis]
29 Cloyd JM, Pawlik TM. Diagnostic and therapeutic implications of novel peptides in hepatocellular carcinoma. Hepatology 2018;68:1223-5. [PMID: 29626850 DOI: 10.1002/hep.29923] [Reference Citation Analysis]
30 Wu V, McArthur MA, Allen A, Manon L, Xie KL. Rare primary hepatic malignancies: A case-based review. Clin Imaging 2021;69:196-204. [PMID: 32919206 DOI: 10.1016/j.clinimag.2020.08.004] [Reference Citation Analysis]
31 Iacuzzi V, Zanchetta M, Gagno S, Poetto AS, Orleni M, Marangon E, Guardascione M, Foltran L, Posocco B, Toffoli G. A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. Journal of Pharmaceutical and Biomedical Analysis 2020;187:113358. [DOI: 10.1016/j.jpba.2020.113358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
32 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
33 Lei GY, Shen L, Junnarkar SP, Huey CT, Low J, Shelat VG. Predictors of 90-Day Mortality following Hepatic Resection for Hepatocellular Carcinoma. Visc Med 2021;37:102-9. [PMID: 33981750 DOI: 10.1159/000510811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Du Z, Chen W, Xia Q, Shi O, Chen Q. Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res 2020;8:16. [PMID: 32435498 DOI: 10.1186/s40364-020-00195-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Mazzoccoli G, Miele L, Marrone G, Mazza T, Vinciguerra M, Grieco A. A Role for the Biological Clock in Liver Cancer. Cancers (Basel) 2019;11:E1778. [PMID: 31718031 DOI: 10.3390/cancers11111778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
37 Li L, Wang H, Yang J, Jiang L, Yang J, Wu H, Wen T, Yan L. Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2018;8:12561. [PMID: 30135506 DOI: 10.1038/s41598-018-30906-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
38 McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling Progress Toward Elimination of Hepatitis B in Australia. Hepatology 2020;71:1170-81. [PMID: 31419332 DOI: 10.1002/hep.30899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
39 Ye HL, Zhang JW, Chen XZ, Wu PB, Chen L, Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci 2020;242:117175. [PMID: 31843528 DOI: 10.1016/j.lfs.2019.117175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
40 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
41 Liang Y, Chen X, Tao Z, Ma M, Adah D, Li X, Dai L, Ding W, Fanuel S, Zhao S, Qin L, Chen X, Zhang X. Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial‑mesenchymal transition. Mol Med Rep 2021;23:418. [PMID: 33846776 DOI: 10.3892/mmr.2021.12057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Luo J, Zheng J, Hao W, Zeng H, Zhang Z, Shao G. lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR-326/hnRNPA2B1 axis in liver cancer. Oncol Lett 2021;21:471. [PMID: 33907581 DOI: 10.3892/ol.2021.12732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Takamoto T, Makuuchi M. Precision surgery for primary liver cancer. Cancer Biol Med 2019;16:475-85. [PMID: 31565478 DOI: 10.20892/j.issn.2095-3941.2019.0194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
45 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology. 2021;73:661-673. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Buchanan R, Sinclair JMA. Alcohol use disorder and the liver. Addiction 2021;116:1270-8. [PMID: 32710592 DOI: 10.1111/add.15204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yang X, Liu Q, Zou J, Li YK, Xie X. Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC). Cancer Manag Res 2021;13:5683-98. [PMID: 34295189 DOI: 10.2147/CMAR.S316588] [Reference Citation Analysis]
48 Zarisfi M, Nguyen T, Nedrow JR, Le A. The Heterogeneity Metabolism of Renal Cell Carcinomas. Adv Exp Med Biol 2021;1311:117-26. [PMID: 34014538 DOI: 10.1007/978-3-030-65768-0_8] [Reference Citation Analysis]
49 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
50 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lin HD, Tseng YK, Yuh CH, Chen SC. Low concentrations of 4-ABP promote liver carcinogenesis in human liver cells and a zebrafish model. J Hazard Mater 2021;423:126954. [PMID: 34474361 DOI: 10.1016/j.jhazmat.2021.126954] [Reference Citation Analysis]
52 Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020;7:11-17. [PMID: 32104669 DOI: 10.2147/jhc.s187121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
53 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Olusanya J, Ifegwu IK, Awosemo AO, Eastwood J, Page A. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990-2016. Trop Med Health 2018;46:34. [PMID: 30262990 DOI: 10.1186/s41182-018-0114-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
58 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
59 Zhao H, Liu S, Zhao H, Liu Y, Xue M, Zhang H, Qiu X, Sun Z, Liang H. Protective effects of fucoidan against ethanol-induced liver injury through maintaining mitochondrial function and mitophagy balance in rats. Food Funct 2021;12:3842-54. [PMID: 33977968 DOI: 10.1039/d0fo03220d] [Reference Citation Analysis]
60 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
61 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
62 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
63 Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology 2021;73:2342-60. [PMID: 33140851 DOI: 10.1002/hep.31614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Reference Citation Analysis]
65 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
66 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
67 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
68 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
69 Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother 2020;28:2040206620921331. [PMID: 32418480 DOI: 10.1177/2040206620921331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Lin JZ, Bai Y, Wang AQ, Long JY, Xu WY, Hu K, Zhao L, Pan J, Sang XT, Zhao HT. Multidisciplinary management of hepatobiliary tumors in the era of precision medicine. Hepatobiliary Pancreat Dis Int 2018;17:381-2. [PMID: 30082196 DOI: 10.1016/j.hbpd.2018.07.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
72 Zhao WT, Lin XL, Liu Y, Han LX, Li J, Lin TY, Shi JW, Wang SC, Lian M, Chen HW, Sun Y, Xu K, Jia JS, Luo RC, Xiao D. miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2. Lab Invest 2019;99:1484-500. [PMID: 31201367 DOI: 10.1038/s41374-019-0270-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
73 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Zhang G, Cao F, Shi L, Ma T, Zhang L. Contribution of high body mass index and alcohol use to liver cancer-related mortality: A study based on 195 countries or territories. Digestive and Liver Disease 2020;52:221-31. [DOI: 10.1016/j.dld.2019.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
76 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
77 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
79 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
80 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Lobo DA, Ginestra P, Ceretti E, Miquel TP, Ciurana J. Cancer Cell Direct Bioprinting: A Focused Review. Micromachines (Basel) 2021;12:764. [PMID: 34203530 DOI: 10.3390/mi12070764] [Reference Citation Analysis]
82 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
85 Chong YC, Lim TE, Fu Y, Shin EM, Tergaonkar V, Han W. Indian Hedgehog links obesity to development of hepatocellular carcinoma. Oncogene 2019;38:2206-22. [PMID: 30470823 DOI: 10.1038/s41388-018-0585-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
86 Marta GN, da Fonseca LG, Braghiroli MI, Moura F, Hoff PM, Sabbaga J. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics (Sao Paulo) 2021;76:e2498. [PMID: 33503195 DOI: 10.6061/clinics/2021/e2498] [Reference Citation Analysis]
87 Liu HY, Lee Y, McLean K, Leggett D, Hodgkinson P, Fawcett J, Mott R, Stuart K, Pryor D. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service. Clin Oncol (R Coll Radiol) 2020;32:e194-202. [PMID: 32345457 DOI: 10.1016/j.clon.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
88 Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:4317-4345. [PMID: 33197225 DOI: 10.1200/jco.20.02672] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
89 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Reference Citation Analysis]
90 Alves-Bezerra M, Furey N, Johnson CG, Bissig KD. Using CRISPR/Cas9 to model human liver disease. JHEP Rep 2019;1:392-402. [PMID: 32039390 DOI: 10.1016/j.jhepr.2019.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
91 Ho JL, Konda A, Rahman J, Harris E, Korn R, Sabir A, Bawany B, Gulati R, Harris GJ, Boswell WD, Fong Y, Rahmanuddin S. Comparative analysis of three-dimensional volume rendering and maximum intensity projection for preoperative planning in liver cancer. Eur J Radiol Open 2020;7:100259. [PMID: 32944595 DOI: 10.1016/j.ejro.2020.100259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Wei H, Jiang H, Liu X, Qin Y, Zheng T, Liu S, Zhang X, Song B. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Eur J Radiol 2020;132:109312. [PMID: 33022551 DOI: 10.1016/j.ejrad.2020.109312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
94 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
95 Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Reference Citation Analysis]
96 Zhang Y, Wang Y. Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances. Front Oncol 2021;11:667428. [PMID: 34055634 DOI: 10.3389/fonc.2021.667428] [Reference Citation Analysis]
97 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749-4763 [PMID: 31528099 DOI: 10.3748/wjg.v25.i32.4749] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
99 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
101 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
102 Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, Lu W, Li S, Xu H, Ouyang G. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med 2022. [PMID: 34989144 DOI: 10.1002/cam4.4530] [Reference Citation Analysis]
103 Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, Ishida Y, Sozzi V, Revill PA, Saito T, Chayama K, Liang TJ. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 2021:S0168-8278(21)01960-7. [PMID: 34363922 DOI: 10.1016/j.jhep.2021.07.030] [Reference Citation Analysis]
104 Raoul JL, Raimbourg J, Hiret S, Adhoute X, Senellart H. [Hepatocellular carcinoma: Increase in incidence or future plague?]. Bull Cancer 2018;105:502-7. [PMID: 29567280 DOI: 10.1016/j.bulcan.2018.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
106 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Nguyen T, Le A. The Metabolism of Renal Cell Carcinomas and Liver Cancer. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2018. pp. 107-18. [DOI: 10.1007/978-3-319-77736-8_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J 2021. [PMID: 34918471 DOI: 10.1002/ueg2.12188] [Reference Citation Analysis]
109 Diniz PHC, Silva SDDC, Faria LC, Vidigal PVT, Ferrari TCA. Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics (Sao Paulo) 2020;75:e1529. [PMID: 32520221 DOI: 10.6061/clinics/2020/e1529] [Reference Citation Analysis]
110 Sutton TL, Billingsley KG, Walker BS, Enestvedt CK, Dewey EN, Orloff SL, Mayo SC. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg 2021;221:1182-7. [PMID: 33707077 DOI: 10.1016/j.amjsurg.2021.02.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Salman A, Aon M, Hussein A, Salman M, Tourky M, Mahmoud A, Aljarad F, Elkaseer M, Shaaban HE, Moustafa A, El-Mikkawy A, Gaballa N, Abdallah H, Zaky Rashed ZF, Elkassar H. Impact of Hypothyroidism on Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Int J Gen Med 2021;14:5711-8. [PMID: 34557025 DOI: 10.2147/IJGM.S326315] [Reference Citation Analysis]
112 He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
113 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
115 Loi M, Comito T, Franzese C, Desideri I, Dominici L, Lo Faro L, Clerici E, Franceschini D, Baldaccini D, Badalamenti M, Reggiori G, Lobefalo F, Scorsetti M. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Geriatr Oncol 2021;12:1100-3. [PMID: 33461945 DOI: 10.1016/j.jgo.2021.01.001] [Reference Citation Analysis]
116 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Hou PP, Luo LJ, Chen HZ, Chen QT, Bian XL, Wu SF, Zhou JX, Zhao WX, Liu JM, Wang XM, Zhang ZY, Yao LM, Chen Q, Zhou D, Wu Q. Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment. Mol Cell 2020;78:1192-1206.e10. [PMID: 32470318 DOI: 10.1016/j.molcel.2020.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
118 Huang Y, Chen S, Qin W, Wang Y, Li L, Li Q, Yuan X. A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2020;10:580513. [PMID: 33251144 DOI: 10.3389/fonc.2020.580513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
119 Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One 2020;15:e0232449. [PMID: 32379785 DOI: 10.1371/journal.pone.0232449] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
120 Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762. Front Pharmacol 2021;12:678620. [PMID: 34012402 DOI: 10.3389/fphar.2021.678620] [Reference Citation Analysis]
121 Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: The current status. The Surgeon 2020;18:178-86. [DOI: 10.1016/j.surge.2019.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
122 Kukla DA, Khetani SR. Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine. Semin Liver Dis 2021;41:368-92. [PMID: 34139785 DOI: 10.1055/s-0041-1731016] [Reference Citation Analysis]
123 Caviglia GP, Olivero A, Rosso C, Bosco C, Ribaldone DG, Fagoonee S. Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. Minerva Biotecnol 2018;30. [DOI: 10.23736/s1120-4826.18.02428-x] [Cited by in Crossref: 12] [Article Influence: 3.0] [Reference Citation Analysis]
124 Bin Y, Ding Y, Xiao W, Liao A. RASSF1A: A promising target for the diagnosis and treatment of cancer. Clin Chim Acta 2020;504:98-108. [PMID: 31981586 DOI: 10.1016/j.cca.2020.01.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Lin CH, Elkholy KH, Wani NA, Li D, Hu P, Barajas JM, Yu L, Zhang X, Jacob ST, Khan WN, Bai XF, Noonan AM, Ghoshal K. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. Mol Cancer Ther 2020;19:384-96. [PMID: 31582534 DOI: 10.1158/1535-7163.MCT-19-0135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
126 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Reference Citation Analysis]
127 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Ocker M. Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 279-290 [PMID: 31988589 DOI: 10.3748/wjg.v26.i3.279] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
130 Sorop A, Iacob R, Iacob S, Constantinescu D, Chitoiu L, Fertig TE, Dinischiotu A, Chivu-Economescu M, Bacalbasa N, Savu L, Gheorghe L, Dima S, Popescu I. Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening. Front Genet 2020;11:712. [PMID: 32793278 DOI: 10.3389/fgene.2020.00712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
131 Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Reference Citation Analysis]
132 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2019;25:80-9. [PMID: 30190369 DOI: 10.1158/1078-0432.CCR-18-0847] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
134 Zhao T, Guo BJ, Xiao CL, Chen JJ, Lü C, Fang FF, Li B. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med 2021;19:418-27. [PMID: 34454893 DOI: 10.1016/j.joim.2021.08.003] [Reference Citation Analysis]
135 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
136 Mu XM, Wang W, Wu FY, Jiang YY, Ma LL, Feng J. Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data. Int J Environ Res Public Health 2020;17:E8028. [PMID: 33142785 DOI: 10.3390/ijerph17218028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Chen Q, Chen AZ, Jia G, Li J, Zheng C, Chen K. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34738743 DOI: 10.1002/hep4.1850] [Reference Citation Analysis]
139 Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y, Kohashi K, Oda Y, Mori M. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Hepatology 2020;72:1987-99. [PMID: 32112577 DOI: 10.1002/hep.31206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
140 Aggarwal M, Arain A, Jin Z. Systemic treatment for hepatocellular carcinoma. Chronic Dis Transl Med 2018;4:148-55. [PMID: 30276361 DOI: 10.1016/j.cdtm.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
141 Hu J, Zhang ZQ, Zhu W, Wu ZR, You Y, Liu Y, Su DW, Wang YB, Gong JP. Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background. Carcinogenesis 2020;41:1576-82. [PMID: 32188964 DOI: 10.1093/carcin/bgaa024] [Reference Citation Analysis]
142 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
143 Adhoute X, Castellani P, Bourlière M. Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma. Transl Gastroenterol Hepatol 2017;2:110. [PMID: 29354767 DOI: 10.21037/tgh.2017.12.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
144 Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. [PMID: 33595662 DOI: 10.1001/jamanetworkopen.2020.37512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Bai Y, Xie F, Miao F, Long J, Huang S, Huang H, Lin J, Wang D, Yang X, Bian J, Mao J, Wang X, Mao Y, Sang X, Zhao H. The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. Aging (Albany NY) 2019;11:5158-72. [PMID: 31339860 DOI: 10.18632/aging.102110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
146 Barzi A, Zhou K, Wang S, Dodge JL, El-Khoueiry A, Setiawan VW. Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers (Basel) 2021;13:3476. [PMID: 34298690 DOI: 10.3390/cancers13143476] [Reference Citation Analysis]
147 Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4:577-587. [PMID: 32258952 DOI: 10.1002/hep4.1491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Mittler J, Heinrich S, Lang H. [Indications for transplantation and bridging procedures for primary hepatobiliary malignancies]. Chirurg 2018;89:865-71. [PMID: 30238348 DOI: 10.1007/s00104-018-0733-z] [Reference Citation Analysis]
149 Zheng S, Zhang Y, Chen S, Zhang Z, Chen F, Zhang Z, Hu Z, Tian J, Wang L. A preliminary study of dual-band confocal laser endomicroscopy combined with image mosaic in the diagnosis of liver cancer. Nanomedicine 2020;29:102250. [PMID: 32619706 DOI: 10.1016/j.nano.2020.102250] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, Zhang L, Chen P, Wang S, Lao XQ, Tse LA, Xu W, Zheng ZJ, Wong MCS. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer 2021;10:330-45. [PMID: 34414121 DOI: 10.1159/000515304] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
152 Wang P, Peng J, Gong Y, Shen N. CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population. Mol Biol Rep 2020;47:3361-8. [PMID: 32248384 DOI: 10.1007/s11033-020-05408-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Siddiqui S, Ahmad R, Khan MA, Upadhyay S, Husain I, Srivastava AN. Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells. Sci Rep 2019;9:245. [PMID: 30664656 DOI: 10.1038/s41598-018-36475-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
154 Desai N, Rich NE, Jain MK, Blackwell JM, Murphy CC, Perryman P, McBryde J, Quirk L, Clark C, Villarreal D, Waljee AK, Gopal P, Singal AG. Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. Am J Gastroenterol 2021;116:976-83. [PMID: 33337657 DOI: 10.14309/ajg.0000000000001085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
156 Kihn-Alarcón AJ, Toledo-Ponce MF, Velarde A, Xu X. Liver Cancer in Guatemala: An Analysis of Mortality and Incidence Trends From 2012 to 2016. J Glob Oncol 2019;5:1-8. [PMID: 30835603 DOI: 10.1200/JGO.18.00179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 García-Marchena N, Maza-Quiroga R, Serrano A, Barrios V, Requena-Ocaña N, Suárez J, Chowen JA, Argente J, Rubio G, Torrens M, López-Gallardo M, Marco EM, Castilla-Ortega E, Santín LJ, Rodríguez de Fonseca F, Pavón FJ, Araos P. Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases. J Psychopharmacol 2020;34:1250-60. [PMID: 32536325 DOI: 10.1177/0269881120928176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
158 Lu F, Shah PA, Rao A, Gifford-Hollingsworth C, Chen A, Trey G, Soryal M, Talat A, Aslam A, Nasir B, Choudhry S, Ishtiaq R, Sanoff H, Conteh LF, Noonan A, Hu KQ, Schmidt C, Fu M, Civan J, Xiao G, Lau DT, Lu X. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00271. [PMID: 33512798 DOI: 10.14309/ctg.0000000000000271] [Reference Citation Analysis]
159 Marini TJ, Oppenheimer DC, Baran TM, Rubens DJ, Dozier A, Garra B, Egoavil MS, Quinn RA, Kan J, Ortega RL, Zhao YT, Tamayo L, Carlotto C, Castaneda B. Testing telediagnostic right upper quadrant abdominal ultrasound in Peru: A new horizon in expanding access to imaging in rural and underserved areas. PLoS One 2021;16:e0255919. [PMID: 34379679 DOI: 10.1371/journal.pone.0255919] [Reference Citation Analysis]
160 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
161 Jin Y, Zhang Y, Luo X. circRNA_PTPRA functions as a sponge of miR-582-3p to regulate hepatocellular carcinoma cell proliferation, migration, invasion and apoptosis. Exp Ther Med 2021;22:1276. [PMID: 34594413 DOI: 10.3892/etm.2021.10711] [Reference Citation Analysis]
162 Li Y, Chen SF, Dong XJ, Zhao XJ. Prediction of cause-specific disability-adjusted life years in China from 2018 through 2021: a systematic analysis. Public Health 2020;180:90-9. [PMID: 31875529 DOI: 10.1016/j.puhe.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Dulskas A, Kavaliauskas P, Zagminas K, Jancoriene L, Smailyte G. Trends in Incidence and Mortality of Primary Liver Cancer in Lithuania 1998-2015. Int J Environ Res Public Health 2021;18:1191. [PMID: 33572744 DOI: 10.3390/ijerph18031191] [Reference Citation Analysis]
164 Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019;12:10335-10342. [PMID: 31819517 DOI: 10.2147/ott.s214870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
165 Alcedo KP, Guerrero A, Basrur V, Fu D, Richardson ML, McLane JS, Tsou CC, Nesvizhskii AI, Welling TH, Lebrilla CB, Otey CA, Kim HJ, Omary MB, Snider NT. Tumor-Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma. Hepatol Commun 2019;3:1400-14. [PMID: 31592495 DOI: 10.1002/hep4.1410] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
166 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Iwata H, Ogino H, Hattori Y, Nakajima K, Nomura K, Hashimoto S, Hayashi K, Toshito T, Sasaki S, Mizoe JE, Shibamoto Y. A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2021;111:117-26. [PMID: 33798564 DOI: 10.1016/j.ijrobp.2021.03.049] [Reference Citation Analysis]
168 Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
171 Kim SS, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, Nam SW, Cheong JY, Eun JW. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14:2646-2659. [PMID: 32525601 DOI: 10.1002/1878-0261.12745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
172 Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis. Hepatology 2021;73:644-60. [PMID: 32298475 DOI: 10.1002/hep.31280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
173 Liu K, McCaughan GW. How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma. Expert Opin Pharmacother 2018;19:1167-70. [PMID: 30011239 DOI: 10.1080/14656566.2018.1498843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
174 Carbone A, De Santis E, Cela O, Giambra V, Miele L, Marrone G, Grieco A, Buschbeck M, Capitanio N, Mazza T, Mazzoccoli G. The Histone Variant MacroH2A1 Impacts Circadian Gene Expression and Cell Phenotype in an In Vitro Model of Hepatocellular Carcinoma. Biomedicines 2021;9:1057. [PMID: 34440260 DOI: 10.3390/biomedicines9081057] [Reference Citation Analysis]
175 Wu CH, Chen CY, Yeh CT, Lin KH. Radiosensitization of Hepatocellular Carcinoma through Targeting Radio-Associated MicroRNA. Int J Mol Sci 2020;21:E1859. [PMID: 32182776 DOI: 10.3390/ijms21051859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
176 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
177 Lin L, Yan L, Liu Y, Yuan F, Li H, Ni J. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 2019;12:96. [PMID: 31511035 DOI: 10.1186/s13045-019-0783-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
178 Aujay G, Debordeaux F, Blanc JF, Lapuyade B, Papadopoulos P, Bordenave L, Trillaud H, Pinaquy JB. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. Nucl Med Commun 2021;42:633-8. [PMID: 33660694 DOI: 10.1097/MNM.0000000000001383] [Reference Citation Analysis]
179 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
180 Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, Hudert CA, Kalveram L, Wiegand S, Saez-Rodriguez J, Longerich T, Hengstler JG, Trautwein C. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol 2021;74:638-48. [PMID: 33342543 DOI: 10.1016/j.jhep.2020.09.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
181 Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147:317-330. [PMID: 31597196 DOI: 10.1002/ijc.32723] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
182 Pang Y, Kartsonaki C, Lv J, Millwood IY, Yu C, Guo Y, Chen Y, Bian Z, Yang L, Chen J, Clarke R, Walters R, Wu S, Li H, Holmes MV, Li L, Chen Z. Observational and Genetic Associations of Body Mass Index and Hepatobiliary Diseases in a Relatively Lean Chinese Population. JAMA Netw Open 2020;3:e2018721. [PMID: 33006619 DOI: 10.1001/jamanetworkopen.2020.18721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
183 Jiang H, Liu X, Chen J, Wei Y, Lee JM, Cao L, Wu Y, Duan T, Li X, Ma L, Song B. Man or machine?Cancer Imaging. 2019;19:84. [PMID: 31806050 DOI: 10.1186/s40644-019-0266-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
184 Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, Zhang C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol 2021;161:573-80. [PMID: 33551200 DOI: 10.1016/j.ygyno.2021.01.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Li L, Liu JD, Gao GD, Zhang K, Song YW, Li HB. Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR. Cancer Med 2020;9:6399-410. [PMID: 32691991 DOI: 10.1002/cam4.3285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
186 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
187 Fouda MS, Omran MM, Tarek G, Hady A Abdel Wahab A. Development of a novel panel based on micro-RNAs (21, 29a, 200 and 335) and alpha-fetoprotein as diagnostic biomarkers for hepatocellular carcinoma associated with hepatitis C infection. Arab J Gastroenterol 2021;22:28-33. [PMID: 33268243 DOI: 10.1016/j.ajg.2020.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
188 Zhang Q, Xu X, Wu M, Qin T, Wu S, Liu H. MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis. Front Oncol 2020;10:562019. [PMID: 33542895 DOI: 10.3389/fonc.2020.562019] [Reference Citation Analysis]
189 Li W, Xiao H, Wu H, Xu X, Zhang Y. Liver Transplantation Versus Liver Resection for Stage I and II Hepatocellular Carcinoma: Results of an Instrumental Variable Analysis. Front Oncol 2021;11:592835. [PMID: 34123771 DOI: 10.3389/fonc.2021.592835] [Reference Citation Analysis]
190 Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep 2021;3:100232. [PMID: 33748727 DOI: 10.1016/j.jhepr.2021.100232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Zhong W, Liu H, Deng L, Chen G, Liu Y. HBO1 overexpression is important for hepatocellular carcinoma cell growth. Cell Death Dis 2021;12:549. [PMID: 34039960 DOI: 10.1038/s41419-021-03818-1] [Reference Citation Analysis]
192 Liu Y, Li YQ, Huang SH, Li YL, Xia JW, Jia JS, Wei F, Wang JH, Dai GQ, Wang YC, Li XY, Han LX, Zhang XL, Xiang XD, Zhao WT, Xiao D, Lin XL. Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways. Aging (Albany NY) 2021;13:21155-90. [PMID: 34517344 DOI: 10.18632/aging.203402] [Reference Citation Analysis]
193 Luo J, Zhou K, Zhang B, Luo N, Bian J. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosis-Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrast-Enhanced MRI. J Magn Reson Imaging 2020;51:812-23. [PMID: 31245888 DOI: 10.1002/jmri.26845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Jeong DY, Kang TW, Min JH, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Han H. Effect of Perfluorobutane Microbubbles on Radiofrequency Ablation for Hepatocellular Carcinoma: Suppression of Steam Popping and Its Clinical Implication. Korean J Radiol 2020;21:1077-86. [PMID: 32691543 DOI: 10.3348/kjr.2019.0910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
195 Yao R, Zou H, Liao W. Prospect of Circular RNA in Hepatocellular Carcinoma: A Novel Potential Biomarker and Therapeutic Target. Front Oncol. 2018;8:332. [PMID: 30191143 DOI: 10.3389/fonc.2018.00332] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
196 Siyin ST, Liu T, Li W, Yao N, Xu G, Qu J, Chen Y. A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer. BMC Cancer 2020;20:1168. [PMID: 33256656 DOI: 10.1186/s12885-020-07665-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 So R, Chen J, Mehta AJ, Liu S, Strak M, Wolf K, Hvidtfeldt UA, Rodopoulou S, Stafoggia M, Klompmaker JO, Samoli E, Raaschou-Nielsen O, Atkinson R, Bauwelinck M, Bellander T, Boutron-Ruault MC, Brandt J, Brunekreef B, Cesaroni G, Concin H, Forastiere F, van Gils CH, Gulliver J, Hertel O, Hoffmann B, de Hoogh K, Janssen N, Lim YH, Westendorp R, Jørgensen JT, Katsouyanni K, Ketzel M, Lager A, Lang A, Ljungman PL, Magnusson PKE, Nagel G, Simonsen MK, Pershagen G, Peter RS, Peters A, Renzi M, Rizzuto D, Sigsgaard T, Vienneau D, Weinmayr G, Severi G, Fecht D, Tjønneland A, Leander K, Hoek G, Andersen ZJ. Long-term exposure to air pollution and liver cancer incidence in six European cohorts. Int J Cancer 2021. [PMID: 34278567 DOI: 10.1002/ijc.33743] [Reference Citation Analysis]
198 Mahale P, Aka P, Chen X, Pfeiffer RM, Liu P, Groover S, Mendy M, Njie R, Goedert JJ, Kirk GD, Glenn JS, O'Brien TR. Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. J Viral Hepat. 2019;26:738-749. [PMID: 30661282 DOI: 10.1111/jvh.13065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
199 Fiorentino A, Gregucci F, Desideri I, Fiore M, Marino L, Errico A, Di Rito A, Borghetti P, Franco P, Greto D, Donato V. Radiation treatment for adult rare cancers: Oldest and newest indication. Crit Rev Oncol Hematol 2021;159:103228. [PMID: 33508447 DOI: 10.1016/j.critrevonc.2021.103228] [Reference Citation Analysis]
200 Erkan B, Meier J, Clark TJ, Kaplan J, Lambert JR, Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC. PLoS One 2019;14:e0226291. [PMID: 31821360 DOI: 10.1371/journal.pone.0226291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
201 Shah SC, Zhu X, Dai Q, Peek RM, Shrubsole MJ. Magnesium intake is associated with a reduced risk of incident liver cancer, based on an analysis of the NIH-American Association of Retired Persons (NIH-AARP) Diet and Health Study prospective cohort. Am J Clin Nutr 2021;113:630-8. [PMID: 33330925 DOI: 10.1093/ajcn/nqaa326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
202 Wang Y, Wang L, Yu X, Duan J. Overexpression of miR-450 affects the biological behavior of HepG2 cells by targeting DNMT3a. Onco Targets Ther 2019;12:5069-76. [PMID: 31303764 DOI: 10.2147/OTT.S203206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
203 Dar AR, McKillop I, Vickress J, Lock M, Yartsev S. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus 2018;10:e3714. [PMID: 30788203 DOI: 10.7759/cureus.3714] [Reference Citation Analysis]
204 Yammine K, Kamar F, Nasser J, Tayar C, Ghosn M, Chehade F, Daher J, Nicolas G. Single-Institution Experience with Selective Internal Radiation Therapy (SIRT) for the Treatment of Primary and Secondary Hepatic Tumors. Cureus. [DOI: 10.7759/cureus.7628] [Reference Citation Analysis]
205 Tabu K, Mawatari S, Oda K, Taniyama O, Toyodome A, Ijuin S, Sakae H, Kumagai K, Kanmura S, Ido A. Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. Mol Clin Oncol 2021;15:174. [PMID: 34276993 DOI: 10.3892/mco.2021.2336] [Reference Citation Analysis]
206 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
207 Yang J, Zhang X, Liu L, Yang X, Qian Q, Du B. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway. Life Sci 2021;264:118711. [PMID: 33186566 DOI: 10.1016/j.lfs.2020.118711] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
209 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
210 Liu Z, Xu K, Jiang Y, Cai N, Fan J, Mao X, Suo C, Jin L, Zhang T, Chen X. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. Int J Epidemiol. 2021;50:128-142. [PMID: 33349860 DOI: 10.1093/ije/dyaa196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
211 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Reference Citation Analysis]
212 Stippel DL, Wahba R, Bruns CJ, Bunck A, Baues C, Persigehl T. [Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors]. Chirurg 2018;89:872-9. [PMID: 30030546 DOI: 10.1007/s00104-018-0688-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
214 Lu HS, Hsin IF, Chen PH, Yang TC, Chang CY, Huang YH, Hou MC. The indocyanine green retention test as a noninvasive marker for esophageal varices in patients with hepatocellular carcinoma. J Chin Med Assoc 2020;83:737-42. [PMID: 32649412 DOI: 10.1097/JCMA.0000000000000378] [Reference Citation Analysis]
215 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Mak D, Kramvis A. Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma. Arch Virol 2020;165:1815-25. [PMID: 32504396 DOI: 10.1007/s00705-020-04686-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Folschette M, Legagneux V, Poret A, Chebouba L, Guziolowski C, Théret N. A pipeline to create predictive functional networks: application to the tumor progression of hepatocellular carcinoma. BMC Bioinformatics 2020;21:18. [PMID: 31937236 DOI: 10.1186/s12859-019-3316-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2021. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
219 Jiang H, Zhao L, Chen Y, Sun L. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23377. [PMID: 32474975 DOI: 10.1002/jcla.23377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Ye Z, Wang S, Chen W, Zhang X, Chen J, Jiang J, Wang M, Zhang L, Xuan Z. Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer. Oncol Lett 2020;20:1409-17. [PMID: 32724383 DOI: 10.3892/ol.2020.11673] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene 2019;38:7035-45. [PMID: 31409896 DOI: 10.1038/s41388-019-0942-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
222 Cossiga V, Guarino M, Morisco F, Caporaso N. Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease. Hepatobiliary Surg Nutr 2020;9:511-3. [PMID: 32832506 DOI: 10.21037/hbsn.2019.11.27] [Reference Citation Analysis]
223 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
224 Lee HA, Goh HG, Lee YS, Jung YK, Kim JH, Yim HJ, Lee MG, An H, Jeen YT, Yeon JE, Byun KS, Seo YS. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol 2021;21:258. [PMID: 34118869 DOI: 10.1186/s12876-021-01833-2] [Reference Citation Analysis]
225 Liu T, Siyin ST, Yao N, Xu G, Chen YT, Duan N, Li W, Qu J, Liu S. Risk of primary liver cancer associated with gallstones and cholecystectomy: A competing risks analysis. Medicine (Baltimore) 2020;99:e22428. [PMID: 32991479 DOI: 10.1097/MD.0000000000022428] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Gabelloni M, Di Nasso M, Morganti R, Faggioni L, Masi G, Falcone A, Neri E. Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings. Radiol Med 2020;125:531-7. [PMID: 32020528 DOI: 10.1007/s11547-020-01142-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
227 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Elhendawy M, Abdul-Baki EA, Abd-Elsalam S, Hagras MM, Zidan AA, Abdel-Naby AY, Watny M, Elkabash IA, Salem ML, Elshanshoury M, Soliman S, Abdou S. MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers. Mol Biol Rep 2020;47:4945-53. [PMID: 32430845 DOI: 10.1007/s11033-020-05521-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
229 Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70:684-691. [PMID: 30529387 DOI: 10.1016/j.jhep.2018.11.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
230 von Olshausen G, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, Zhang K, Odenthal M, Ringelhan M, Niessen CM, Protzer U. Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion. Oncotarget 2018;9:33947-60. [PMID: 30338037 DOI: 10.18632/oncotarget.26103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
231 Miller H, Czigany Z, Lurje I, Reichelt S, Bednarsch J, Strnad P, Trautwein C, Roderburg C, Tacke F, Gaisa NT, Knüchel-Clarke R, Neumann UP, Lurje G. Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers (Basel) 2020;12:E3826. [PMID: 33352897 DOI: 10.3390/cancers12123826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Pohl K, Moodley P, Dhanda AD. Alcohol's Impact on the Gut and Liver. Nutrients 2021;13:3170. [PMID: 34579046 DOI: 10.3390/nu13093170] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Fan J, Liu Z, Mao X, Tong X, Zhang T, Suo C, Chen X. Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017. Cancer Med 2020;9:6875-87. [PMID: 32750217 DOI: 10.1002/cam4.3338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
234 Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology 2018;69:60-9. [DOI: 10.1016/j.jhep.2018.02.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
235 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Shuai T, Zhou Y, Shao G, Yang R, Wang L, Wang J, Sun J, Ren L, Wang J, Liao Y, Wei M, Xu Q, Li Y, Zhao L. Bimodal Molecule as NIR-CT Contrast Agent for Hepatoma Specific Imaging. Anal Chem 2020;92:1138-46. [PMID: 31820637 DOI: 10.1021/acs.analchem.9b04212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
237 Fang C, Li W, Yin R, Zhu D, Liu X, Wu H, Wang Q, Wang W, Bai Q, Chen B, Yao X, Chen Y. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway. Sci Rep 2021;11:16507. [PMID: 34389740 DOI: 10.1038/s41598-021-93055-5] [Reference Citation Analysis]
238 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
239 Chen W, Huang L, Liang J, Ye Y, Yu S, Zhang Y. Long noncoding RNA small nucleolar RNA host gene 15 deteriorates liver cancer via microRNA-18b-5p/LIM-only 4 axis. IUBMB Life 2021;73:349-61. [PMID: 33372376 DOI: 10.1002/iub.2431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Onozuka D, Nakamura Y, Tsuji G, Furue M. Mortality in Yusho patients exposed to polychlorinated biphenyls and polychlorinated dibenzofurans: a 50-year retrospective cohort study. Environ Health 2020;19:119. [PMID: 33228703 DOI: 10.1186/s12940-020-00680-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
241 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Li L, Liu C, Yang J, Wu H, Wen T, Wang W, Li B, Yan L. Early postoperative controlling nutritional status (CONUT) score is associated with complication III-V after hepatectomy in hepatocellular carcinoma: A retrospective cohort study of 1,334 patients. Sci Rep 2018;8:13406. [PMID: 30194336 DOI: 10.1038/s41598-018-31714-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
243 Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther 2019;12:2149-57. [PMID: 30962696 DOI: 10.2147/OTT.S197326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
244 Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo 2019;33:1411-20. [PMID: 31471386 DOI: 10.21873/invivo.11618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
245 Underhill GH, Khetani SR. Emerging trends in modeling human liver disease in vitro. APL Bioeng 2019;3:040902. [PMID: 31893256 DOI: 10.1063/1.5119090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
246 Kage H, Flodby P, Zhou B, Borok Z. Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice. Cell Mol Life Sci 2019;76:4663-72. [PMID: 31332482 DOI: 10.1007/s00018-019-03238-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
247 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
248 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
249 Opneja A, Cioffi G, Alahmadi A, Jones N, Tang TY, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Mangla A, Barnholtz-Sloan J, Lee RT. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Cancer Med 2021;10:4397-404. [PMID: 34060249 DOI: 10.1002/cam4.3985] [Reference Citation Analysis]
250 Hajighasemlou S, Nikbakht M, Pakzad S, Muhammadnejad S, Gharibzadeh S, Mirmoghtadaei M, Zafari F, Seyhoun I, Ai J, Verdi J. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evid Based Complement Alternat Med 2020;2020:9602728. [PMID: 32617114 DOI: 10.1155/2020/9602728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19:1941-1948. [PMID: 30345837 DOI: 10.1080/14656566.2018.1534956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
252 Geist BK, Wang J, Wang X, Lin J, Yang X, Zhang H, Li F, Zhao H, Hacker M, Huo L, Li X. Comparison of different kinetic models for dynamic 18 F-FDG PET/CT imaging of hepatocellular carcinoma with various, also dual-blood input function. Phys Med Biol 2020;65:045001. [DOI: 10.1088/1361-6560/ab66e3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
253 Sternby Eilard M, Åberg F. Combination of biomarkers for the detection of hepatocellular carcinoma. Ann Transl Med 2020;8:1283. [PMID: 33209863 DOI: 10.21037/atm-20-5798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H, Shimizu M, Tanaka T, Hara A. Virus-Driven Carcinogenesis. Cancers (Basel) 2021;13:2625. [PMID: 34071792 DOI: 10.3390/cancers13112625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci 2021;22:13578. [PMID: 34948375 DOI: 10.3390/ijms222413578] [Reference Citation Analysis]
256 Li TH, Tsai YL, Hsu CF, Liu CW, Huang CC, Yang YY, Tsai HC, Huang SF, Hsieh YC, Liu HM, Lee TY, Hou MC, Tsai CY, Lin HC. Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis. Gastroenterol Res Pract 2020;2020:1892584. [PMID: 32454812 DOI: 10.1155/2020/1892584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World J Gastroenterol 2020; 26(17): 2040-2048 [PMID: 32536773 DOI: 10.3748/wjg.v26.i17.2040] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
258 Mak D, Sengayi M, Chen WC, Babb de Villiers C, Singh E, Kramvis A. Liver cancer mortality trends in South Africa: 1999-2015.BMC Cancer. 2018;18:798. [PMID: 30086727 DOI: 10.1186/s12885-018-4695-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
259 De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, Burlone ME, Minisini R, Pirisi M. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:4216451. [PMID: 32382265 DOI: 10.1155/2020/4216451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
260 Cao SQ, Zheng H, Sun BC, Wang ZL, Liu T, Guo DH, Shen ZY. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion. World J Gastroenterol 2019; 25(35): 5283-5299 [PMID: 31558873 DOI: 10.3748/wjg.v25.i35.5283] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
261 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Reference Citation Analysis]
262 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
263 Huang W, Yu D, Wang M, Han Y, Lin J, Wei D, Cai J, Li B, Chen P, Zhang X. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma. Cell Prolif 2020;53:e12836. [PMID: 32537856 DOI: 10.1111/cpr.12836] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
264 Chen Y, He C, Wen T, Yan L, Yang J. The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis. Asia Pac J Clin Oncol 2021;17:e238-48. [PMID: 33124200 DOI: 10.1111/ajco.13458] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Reference Citation Analysis]
266 Yi Q, Liu J, Alexia K, Li J, Luo H, Sun J. [Over-expression of miR-144 inhibits invasion of liver cancer SMMC-7721 cells in vitro by suppressing TLR/MyD88 pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:765-71. [PMID: 32897198 DOI: 10.12122/j.issn.1673-4254.2020.05.25] [Reference Citation Analysis]
267 Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther 2020;52:866-76. [DOI: 10.1111/apt.15976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
268 Huang KW, Jayant K, Lee PH, Yang PC, Hsiao CY, Habib N, Sodergren MH. Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. J Clin Med 2019;8:E385. [PMID: 30893948 DOI: 10.3390/jcm8030385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
269 Weaver AJ, Stafford R, Hale J, Denning D, Sanabria JR; GBD Collaborators. Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017. J Surg Res 2020;245:89-98. [PMID: 31404895 DOI: 10.1016/j.jss.2019.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
270 Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int 2019;39:1098-108. [PMID: 30829446 DOI: 10.1111/liv.14087] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
271 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
272 Huang SC, Liang JD, Hsu SJ, Hong TC, Yang HC, Kao JH. Direct comparison of biopsy techniques for hepatic malignancies. Clin Mol Hepatol 2021;27:305-12. [PMID: 33317239 DOI: 10.3350/cmh.2020.0301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
273 Liu Q, Gao P, Li Q, Xu C, Qu K, Zhang J. Long non-coding RNA SNHG16 as a potential biomarker in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27178. [PMID: 34516515 DOI: 10.1097/MD.0000000000027178] [Reference Citation Analysis]
274 Wong YJ, Qiu TY, Ng GK, Zheng Q, Teo EK. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:615-23. [PMID: 33606427 DOI: 10.1097/MCG.0000000000001478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
275 Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technol Cancer Res Treat 2018;17:1533033818790217. [PMID: 30068240 DOI: 10.1177/1533033818790217] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
276 Lee YS, Jung YK, Kim JH, Cho SB, Kim DY, Kim MY, Kim HJ, Seo YS, Yoon KT, Hong YM, Lee JH, Lee HW, Yim HJ, Jang BK, Jang ES, Jang JY, Hwang SY. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer 2020;140:19-27. [PMID: 33039810 DOI: 10.1016/j.ejca.2020.09.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, Oh SN, Rha SE. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2021;22:1289-99. [PMID: 34047507 DOI: 10.3348/kjr.2020.1394] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
278 Kang TW, Kong SY, Kang D, Kang MW, Kim YK, Kim SH, Sinn DH, Kim YA, Choi KS, Lee ES, Woo SM, Back JH, Guallar E, Cho J. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. Radiology 2020;295:114-24. [PMID: 32013789 DOI: 10.1148/radiol.2020190639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
279 Tseng GW, Lin MC, Lai SW, Peng CY, Chuang PH, Su WP, Kao JT, Lai HC. Do peripartum and postmenopausal women with primary liver cancer have a worse prognosis? A nationwide cohort in Taiwan. World J Hepatol 2021; 13(11): 1766-1776 [PMID: 34904044 DOI: 10.4254/wjh.v13.i11.1766] [Reference Citation Analysis]
280 Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine M. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. J Infect Dis 2021:jiab327. [PMID: 34160616 DOI: 10.1093/infdis/jiab327] [Reference Citation Analysis]
281 Bai J, Liu Z, Liu J, Zhang S, Tian Y, Zhang Y, Ren L, Kong D. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging (Albany NY) 2019;11:12452-75. [PMID: 31881007 DOI: 10.18632/aging.102582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
282 Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Sun W. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J Clin Med 2020;9:E2682. [PMID: 32824968 DOI: 10.3390/jcm9092682] [Reference Citation Analysis]
283 Dikilitas M. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better? J Gastrointest Cancer 2020;51:1193-6. [PMID: 32869146 DOI: 10.1007/s12029-020-00497-7] [Reference Citation Analysis]
284 Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2776. [PMID: 32998218 DOI: 10.3390/cancers12102776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
285 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
286 Zhang H, Liang H, Wu S, Zhang Y, Yu Z. MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2). Environ Toxicol Pharmacol 2021;82:103559. [PMID: 33290872 DOI: 10.1016/j.etap.2020.103559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
287 Huang JF, Huang CF, Yeh ML, Dai CY, Yu ML, Chuang WL. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? Expert Rev Anti Infect Ther. 2018;16:907-912. [PMID: 30396303 DOI: 10.1080/14787210.2018.1544492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
288 Carr J, Cha DE, Shaltiel T, Zheng S, Siderides C, Golas B, Labow D, Magge D, Cohen N, Branch A, Sarpel U. African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality. J Immigr Minor Health 2021. [PMID: 33907933 DOI: 10.1007/s10903-021-01205-8] [Reference Citation Analysis]
289 Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med 2020;2:337-42. [PMID: 33330829 DOI: 10.35772/ghm.2020.01059] [Reference Citation Analysis]
290 Ma C, Yang Y, Xu L, Tu W, Chen F, Wang J. Rce1 suppresses invasion and metastasis of hepatocellular carcinoma via epithelial-mesenchymal transition induced by the TGF-β1/H-Ras signaling pathway. J Cell Physiol 2020;235:2506-20. [PMID: 31506952 DOI: 10.1002/jcp.29155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Ohtsuka S, Aramaki T, Uesaka K. Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. Ann Gastroenterol Surg 2021;5:553-66. [PMID: 34337304 DOI: 10.1002/ags3.12451] [Reference Citation Analysis]
292 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
293 O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, Asiki G, Seeley J, Matthews PC, Newton R. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open 2020;10:e032890. [PMID: 32234740 DOI: 10.1136/bmjopen-2019-032890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
294 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
295 Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, Lee HC, Jung J, Park JH, Kim JH, Kim SY, Yoon SM. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol 2021;36:1962-70. [PMID: 33594690 DOI: 10.1111/jgh.15442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Wang F, Mubarik S, Zhang Y, Wang L, Wang Y, Yu C, Li H. Long-Term Trends of Liver Cancer Incidence and Mortality in China 1990-2017: A Joinpoint and Age-Period-Cohort Analysis. Int J Environ Res Public Health 2019;16:E2878. [PMID: 31408961 DOI: 10.3390/ijerph16162878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
297 Adadey SM, Languon S, Ayee R, Quansah DN, Quaye O. Incidence and mortality of cancer in the Volta Region of Ghana. Exp Biol Med (Maywood) 2020;245:1058-65. [PMID: 32498552 DOI: 10.1177/1535370220931514] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
298 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
299 Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Patel N, Maher J, Lie X, Gwaltney C, Barzi A, Karwal M, Macarulla T, Sun HC, Trojan J, Meyers O, Workman C, Morgan S, Negro A, Cohen G. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res 2021. [PMID: 34115280 DOI: 10.1007/s11136-021-02903-4] [Reference Citation Analysis]
301 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523-532. [PMID: 32335166 DOI: 10.1016/j.jhep.2020.04.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis]
303 Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, Xia C, Yang Z, Li H, Wei W, Chen W, He J. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571-579. [PMID: 30700925 DOI: 10.21147/j.issn.1000-9604.2018.06.01] [Cited by in Crossref: 62] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
304 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 34.0] [Reference Citation Analysis]
305 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Reference Citation Analysis]
306 Han M, Tran BT, Cho H, Oh JK. Economic burden of alcohol-related cancers in the Republic of Korea. Drug Alcohol Depend 2020;217:108295. [PMID: 32979737 DOI: 10.1016/j.drugalcdep.2020.108295] [Reference Citation Analysis]
307 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
308 Paganoni R, Lechel A, Vujic Spasic M. Iron at the Interface of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4097. [PMID: 33921027 DOI: 10.3390/ijms22084097] [Reference Citation Analysis]
309 Zhu S, Huang X, Zhang K, Tan W, Lin Z, He Q, Chen Y, Shang C. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. Cancer Med 2019;8:7679-92. [PMID: 31674731 DOI: 10.1002/cam4.2618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
310 Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou S, Bai Y, Tang H, Wang X, Zhao M. Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med 2021;9:675. [PMID: 33987373 DOI: 10.21037/atm-21-997] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
311 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Reference Citation Analysis]
312 Daye D, Hu EY, Glazer DI, Tuncali K, Levesque V, Shyn PB. Periprocedural factors associated with overall patient survival following percutaneous image-guided liver tumor cryoablation. Int J Hyperthermia 2022;39:34-9. [PMID: 34937523 DOI: 10.1080/02656736.2021.2013552] [Reference Citation Analysis]
313 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
314 Zhang QW, Wang JY, Qiao XF, Li TL, Li X. Variations in disease burden of laryngeal cancer attributable to alcohol use and smoking in 204 countries or territories, 1990-2019. BMC Cancer 2021;21:1082. [PMID: 34620148 DOI: 10.1186/s12885-021-08814-4] [Reference Citation Analysis]
315 He J, Zuo Q, Hu B, Jin H, Wang C, Cheng Z, Deng X, Yang C, Ruan H, Yu C, Zhao F, Yao M, Fang J, Gu J, Zhou J, Fan J, Qin W, Yang XR, Wang H. A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. Cancer Lett 2019;450:98-109. [PMID: 30790682 DOI: 10.1016/j.canlet.2019.02.033] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
316 Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castañeda-Orjuela CA, Catalá-López F, Choi JJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, das Neves J, Dey S, Dharmaratne SD, Doku DT, Driscoll TR, Dubey M, Ebrahimi H, Edessa D, El-Khatib Z, Endries AY, Fischer F, Force LM, Foreman KJ, Gebrehiwot SW, Gopalani SV, Grosso G, Gupta R, Gyawali B, Hamadeh RR, Hamidi S, Harvey J, Hassen HY, Hay RJ, Hay SI, Heibati B, Hiluf MK, Horita N, Hosgood HD, Ilesanmi OS, Innos K, Islami F, Jakovljevic MB, Johnson SC, Jonas JB, Kasaeian A, Kassa TD, Khader YS, Khan EA, Khan G, Khang YH, Khosravi MH, Khubchandani J, Kopec JA, Kumar GA, Kutz M, Lad DP, Lafranconi A, Lan Q, Legesse Y, Leigh J, Linn S, Lunevicius R, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, McMahon BJ, Meier T, Melaku YA, Melku M, Memiah P, Mendoza W, Meretoja TJ, Mezgebe HB, Miller TR, Mohammed S, Mokdad AH, Moosazadeh M, Moraga P, Mousavi SM, Nangia V, Nguyen CT, Nong VM, Ogbo FA, Olagunju AT, Pa M, Park EK, Patel T, Pereira DM, Pishgar F, Postma MJ, Pourmalek F, Qorbani M, Rafay A, Rawaf S, Rawaf DL, Roshandel G, Safiri S, Salimzadeh H, Sanabria JR, Santric Milicevic MM, Sartorius B, Satpathy M, Sepanlou SG, Shackelford KA, Shaikh MA, Sharif-Alhoseini M, She J, Shin MJ, Shiue I, Shrime MG, Sinke AH, Sisay M, Sligar A, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tessema GA, Topor-Madry R, Tran TT, Tran BX, Ukwaja KN, Vlassov VV, Vollset SE, Weiderpass E, Williams HC, Yimer NB, Yonemoto N, Younis MZ, Murray CJL, Naghavi M; Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2018;4:1553-68. [PMID: 29860482 DOI: 10.1001/jamaoncol.2018.2706] [Cited by in Crossref: 649] [Cited by in F6Publishing: 655] [Article Influence: 216.3] [Reference Citation Analysis]
317 Qiu YA, Xiong J, Yu T. Role of G Protein-Coupled Estrogen Receptor in Digestive System Carcinomas: A Minireview. Onco Targets Ther 2021;14:2611-22. [PMID: 33888991 DOI: 10.2147/OTT.S291896] [Reference Citation Analysis]
318 Kang MK, Choi JH. Parenchymal Extinction Mimicking Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B-Related Liver Cirrhosis. Diagnostics (Basel) 2021;11:1171. [PMID: 34203262 DOI: 10.3390/diagnostics11071171] [Reference Citation Analysis]
319 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
320 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
322 Yang C, Han C, Wang X, Liao X, Liu X, Qin W, Yu L, Zhu G, Su H, Lu S, Chen Z, Yu T, Liu Z, Huang K, Liu Z, Liang Y, Huang J, Peng T. Clinical Implication and the Hereditary Factors of NM23 in Hepatocellular Carcinoma Based on Bioinformatics Analysis and Genome-Wide Association Study. J Oncol 2018;2018:6594169. [PMID: 30662464 DOI: 10.1155/2018/6594169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
323 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
324 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
325 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
326 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
327 Zheng X, Zhang F, Zhao Y, Zhang J, Dawulieti J, Pan Y, Cui L, Sun M, Shao D, Li M, He K, Zhang M, Li J, Chen L. Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics 2018;8:3808-23. [PMID: 30083261 DOI: 10.7150/thno.25255] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
328 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
330 Buganza-torio E, Doucette KE. Management of Viral Hepatitis in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America 2018;32:635-50. [DOI: 10.1016/j.idc.2018.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
331 Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther 2019;49:308-20. [PMID: 30569507 DOI: 10.1111/apt.15082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
332 Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int 2018;38 Suppl 1:115-21. [PMID: 29427482 DOI: 10.1111/liv.13640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
333 Qin Z, Liu X, Li Z, Wang G, Feng Z, Liu Y, Yang H, Tan C, Zhang Z, Li K. LncRNA LINC00667 aggravates the progression of hepatocellular carcinoma by regulating androgen receptor expression as a miRNA-130a-3p sponge. Cell Death Discov 2021;7:387. [PMID: 34907204 DOI: 10.1038/s41420-021-00787-4] [Reference Citation Analysis]
334 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
335 Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Awuku YA, Yeboah-Afihene M. Hepatitis B At-Birth Dose Vaccine: An Urgent Call for Implementation in Ghana. Vaccines (Basel) 2018;6:E15. [PMID: 29534503 DOI: 10.3390/vaccines6010015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
337 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel). 2019;12:49. [PMID: 31877859 DOI: 10.3390/cancers12010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
338 Suzuki N, Tajiri K, Futsukaichi Y, Tanaka S, Murayama A, Entani T, Kobayashi S, Takahashi K, Fujii T, Imura J, Yasuda I. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:63-9. [PMID: 32110202 DOI: 10.1159/000505774] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
339 Li W, Wang Y, Zhou X, Pan X, Lü J, Sun H, Xie Z, Chen S, Gao X. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma. Journal of Ginseng Research 2022;46:167-74. [DOI: 10.1016/j.jgr.2021.06.002] [Reference Citation Analysis]
340 Xiong DD, Feng ZB, Lai ZF, Qin Y, Liu LM, Fu HX, He RQ, Wu HY, Dang YW, Chen G, Luo DZ. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma. Cell Death Dis 2019;10:658. [PMID: 31506425 DOI: 10.1038/s41419-019-1890-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
341 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Jin M, Chen Y, Hu S, Zhu M, Wang Y, Chen M, Peng Z. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Front Oncol 2021;11:751777. [PMID: 34745980 DOI: 10.3389/fonc.2021.751777] [Reference Citation Analysis]
343 Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783-91. [PMID: 33734139 DOI: 10.1097/CM9.0000000000001474] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
344 Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, Bonkovsky HL, Phillips JD, Wang B, K Singal A, M McGuire B, Desnick RJ, Balwani M. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology 2021;73:1736-46. [PMID: 32681675 DOI: 10.1002/hep.31460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
345 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Reference Citation Analysis]
346 Lee GC, Ferrone CR, Vagefi PA, Uppot RN, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Qadan M. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg 2019;218:157-63. [PMID: 30635211 DOI: 10.1016/j.amjsurg.2018.12.067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
347 Sutton TL, Pasko J, Kelly G, Maynard E, Connelly C, Orloff S, Enestvedt CK. Intraoperative autologous transfusion and oncologic outcomes in liver transplantation for hepatocellular carcinoma: a propensity matched analysis. HPB (Oxford) 2021:S1365-182X(21)00615-8. [PMID: 34294524 DOI: 10.1016/j.hpb.2021.06.433] [Reference Citation Analysis]
348 Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Yuan L, Bing Z, Han J, An X, Liu X, Li R, Wang C, Sun X, Yang L, Yang K. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma. Biomed Pharmacother 2020;124:109838. [PMID: 31981943 DOI: 10.1016/j.biopha.2020.109838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
350 Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Hashiguchi T, Imoto Y. Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:9142672. [PMID: 30050894 DOI: 10.1155/2018/9142672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
351 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
352 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Chen X, Lu Y, Shi X, Chen X, Rong D, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma. J Oncol 2021;2021:3002480. [PMID: 34925507 DOI: 10.1155/2021/3002480] [Reference Citation Analysis]
354 Soule E, Matteo J. Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma. Gastrointest Tumors 2018;5:54-61. [PMID: 30574482 DOI: 10.1159/000491694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
355 Zhong C, Liu Z, Zhang X, Pu Y, Yang Z, Bao Y. Physicochemical properties of polysaccharides from Ligusticum chuanxiong and analysis of their anti-tumor potential through immunoregulation. Food Funct 2021;12:1719-31. [PMID: 33502414 DOI: 10.1039/d0fo02978e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Okazaki S, Shibuya K, Shiba S, Okamoto M, Miyasaka Y, Osu N, Kawashima M, Kakizaki S, Araki K, Shirabe K, Ohno T. Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe. Hepatol Res 2021;51:303-12. [PMID: 33350034 DOI: 10.1111/hepr.13606] [Reference Citation Analysis]
357 El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev 2021;98:102221. [PMID: 34029957 DOI: 10.1016/j.ctrv.2021.102221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Peng C, Teng W, Hsieh Y, Jeng W, Huang C, Lui K, Hung C, Chen Y, Lin C, Lin C, Lin S, Sheen I. Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Adv in Digestive Med 2020;7:83-92. [DOI: 10.1002/aid2.13182] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 D'Avola D, Bilbao JI, Sangro B. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. Cardiovasc Intervent Radiol 2019;42:1262-70. [PMID: 31069465 DOI: 10.1007/s00270-019-02221-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
360 Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol 2021:S0168-8278(21)00358-5. [PMID: 34081959 DOI: 10.1016/j.jhep.2021.05.022] [Reference Citation Analysis]
361 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
362 Yan Y, He W, Chen Y, Li Q, Pan J, Yuan Y, Zeng W, Chen D, Xing W. Comprehensive Analysis to Identify the Encoded Gens of Sodium Channels as a Prognostic Biomarker in Hepatocellular Carcinoma. Front Genet 2022;12:802067. [DOI: 10.3389/fgene.2021.802067] [Reference Citation Analysis]
363 Liu H, Shi W, Jin Z, Zhuo R, Dong J, Lao Q, Li S, Pang W. Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017. BMC Cancer 2021;21:459. [PMID: 33894746 DOI: 10.1186/s12885-021-08217-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 2021;21:621-8. [PMID: 33499684 DOI: 10.1080/14737140.2021.1882855] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
365 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
366 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Atyah M, Zhou C, Zhou Q, Chen W, Weng J, Wang P, Shi Y, Dong Q, Ren N. The Age-Specific Features and Clinical Significance of NRF2 and MAPK10 Expression in HCC Patients. IJGM 2022;Volume 15:737-48. [DOI: 10.2147/ijgm.s351263] [Reference Citation Analysis]
369 Álvarez Santos MR, Bueno Duarte Y, Güiza FM, Romero Bohórquez AR, Mendez-Sanchez SC. Effects of new tetrahydroquinoline-isoxazole hybrids on bioenergetics of hepatocarcinoma Hep-G2 cells and rat liver mitochondria. Chem Biol Interact 2019;302:164-71. [PMID: 30738022 DOI: 10.1016/j.cbi.2019.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
370 Behary J, Raposo AE, Amorim NML, Zheng H, Gong L, McGovern E, Chen J, Liu K, Beretov J, Theocharous C, Jackson MT, Seet-Lee J, McCaughan GW, El-Omar EM, Zekry A. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model. BMC Microbiol 2021;21:113. [PMID: 33858327 DOI: 10.1186/s12866-021-02171-9] [Reference Citation Analysis]
371 Melchor SJ, Hatter JA, Castillo ÉAL, Saunders CM, Byrnes KA, Sanders I, Abebayehu D, Barker TH, Ewald SE. T. gondii infection induces IL-1R dependent chronic cachexia and perivascular fibrosis in the liver and skeletal muscle. Sci Rep 2020;10:15724. [PMID: 32973293 DOI: 10.1038/s41598-020-72767-0] [Reference Citation Analysis]
372 Li Z, Gong H, Liu Q, Wu W, Cheng J, Mei Y, Chen Y, Zheng H, Yu X, Zhong S, Li Y. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy. Immunology 2020;159:384-92. [PMID: 31849039 DOI: 10.1111/imm.13168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
373 Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Reference Citation Analysis]
374 Chen ZY, Wang T, Gan X, Chen SH, He YT, Wang YQ, Zhang KH. Cytoskeleton-associated membrane protein 4 is upregulated in tumor tissues and is associated with clinicopathological characteristics and prognosis in hepatocellular carcinoma. Oncol Lett 2020;19:3889-98. [PMID: 32382336 DOI: 10.3892/ol.2020.11499] [Reference Citation Analysis]
375 Khan H, Jia W, Yu Z, Zaib T, Feng J, Jiang Y, Song H, Bai Y, Yang B, Feng H. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2. Biomed Pharmacother 2020;128:110244. [PMID: 32464306 DOI: 10.1016/j.biopha.2020.110244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
376 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
377 Yu SCH, Hui JWY, Chong CCN, Cho CCM, Cheung S, Wong J, Lee KF. Comparison of Survival Outcomes in Transarterial Ethanol Ablation and Liver Resection for Solitary Hepatocellular Carcinoma ≤ 5 cm in Patients Stratified by Liver Function. Cardiovasc Intervent Radiol 2021. [PMID: 34609579 DOI: 10.1007/s00270-021-02768-7] [Reference Citation Analysis]
378 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
379 Ndiaye H, Liu JY, Hall A, Minogue S, Morgan MY, Waugh MG. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases. Biosci Rep 2020;40:BSR20200219. [PMID: 32286604 DOI: 10.1042/BSR20200219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
380 Gabbia D, Cannella L, De Martin S. The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases. Biomedicines 2021;9:687. [PMID: 34204571 DOI: 10.3390/biomedicines9060687] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
381 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
382 Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Cells 2020;9:E746. [PMID: 32197467 DOI: 10.3390/cells9030746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
383 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals. J Infect Dis 2020:jiaa359. [PMID: 32584386 DOI: 10.1093/infdis/jiaa359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
384 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Reference Citation Analysis]
385 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
386 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
387 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
388 Nan Y, Xu X, Gao Y, Wang R, Li W, Yang M, Liu L, Duan Z, Jia J, Wei L, Zhuang H; Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention of primary liver cancer. Hepatol Int 2021;15:1289-300. [PMID: 34846705 DOI: 10.1007/s12072-021-10259-7] [Reference Citation Analysis]
389 Bailey CW, Sydnor MK Jr. Current State of Tumor Ablation Therapies. Dig Dis Sci 2019;64:951-8. [PMID: 30859403 DOI: 10.1007/s10620-019-05514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
390 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
391 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
392 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
393 Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, Chen Z, Chen Z, Luo Z, Wang X, Kong J, Li G, Wang H, Leo HL, Yu H, Xi L, Guo Q. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials 2020;240:119855. [DOI: 10.1016/j.biomaterials.2020.119855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
394 Yang W, Liu Y, Gao R, Xiu Z, Sun T. Knockdown of cZNF292 suppressed hypoxic human hepatoma SMMC7721 cell proliferation, vasculogenic mimicry, and radioresistance. Cell Signal 2019;60:122-35. [PMID: 31028816 DOI: 10.1016/j.cellsig.2019.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
395 Wang WJ, Xiao P, Xu HQ, Niu JQ, Gao YH. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol 2019; 25(12): 1445-1456 [PMID: 30948908 DOI: 10.3748/wjg.v25.i12.1445] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
396 Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020;71:1247-1261. [PMID: 31378984 DOI: 10.1002/hep.30889] [Cited by in Crossref: 65] [Cited by in F6Publishing: 77] [Article Influence: 21.7] [Reference Citation Analysis]
397 Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
398 Umezu T, Tsuneyama K, Kanekura K, Hayakawa M, Tanahashi T, Kawano M, Taguchi YH, Toyoda H, Tamori A, Kuroda M, Murakami Y. Comprehensive analysis of liver and blood miRNA in precancerous conditions. Sci Rep 2020;10:21766. [PMID: 33303811 DOI: 10.1038/s41598-020-78500-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
399 Esposito P, Matteo M, Concepcion C, Montanarella M, Matteo J. Portal Vein Tumor Thrombus: No Longer a Death Sentence. Cureus 2021;13:e12845. [PMID: 33628697 DOI: 10.7759/cureus.12845] [Reference Citation Analysis]
400 Akateh C, Pawlik TM, Cloyd JM. Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B? Ann Transl Med. 2018;6:397. [PMID: 30498725 DOI: 10.21037/atm.2018.08.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
401 Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, Chen X. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med 2019;8:5787-99. [PMID: 31385465 DOI: 10.1002/cam4.2477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
402 Mourad M, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort - a retrospective study. Transpl Int 2021;34:535-45. [PMID: 33449394 DOI: 10.1111/tri.13819] [Reference Citation Analysis]
403 Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, 't Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. J Hepatol 2021;74:535-49. [PMID: 32971137 DOI: 10.1016/j.jhep.2020.09.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
404 Barsouk A, Thandra KC, Saginala K, Rawla P, Barsouk A. Chemical Risk Factors of Primary Liver Cancer: An Update. Hepat Med 2020;12:179-88. [PMID: 33447099 DOI: 10.2147/HMER.S278070] [Reference Citation Analysis]
405 Zhang YW, Chen Q, Li B, Li HY, Zhao XK, Xiao YY, Liu S, Zuo S. NAP1L1 Functions as a Tumor Promoter via Recruiting Hepatoma-Derived Growth Factor/c-Jun Signal in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:659680. [PMID: 34368121 DOI: 10.3389/fcell.2021.659680] [Reference Citation Analysis]
406 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 VoPham T, Bertrand KA, Tamimi RM, Laden F, Hart JE. Ambient PM2.5 air pollution exposure and hepatocellular carcinoma incidence in the United States. Cancer Causes Control 2018;29:563-72. [PMID: 29696510 DOI: 10.1007/s10552-018-1036-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
408 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
409 Guo X, Shao X, Li J, Li S, Li K, Li D. Fruit and vegetable intake and liver cancer risk: a meta-analysis of prospective cohort studies. Food Funct 2019;10:4478-85. [DOI: 10.1039/c9fo00804g] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
410 Marini TJ, Oppenheimer DC, Baran TM, Rubens DJ, Toscano M, Drennan K, Garra B, Miele FR, Garra G, Noone SJ, Tamayo L, Carlotto C, Trujillo L, Waks E, Garra K, Egoavil MS, Berrospi J, Castaneda B. New Ultrasound Telediagnostic System for Low-Resource Areas: Pilot Results From Peru. J Ultrasound Med 2021;40:583-95. [PMID: 32798267 DOI: 10.1002/jum.15420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
411 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
412 Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25(24): 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
413 Yu Z, Song Y, Cai M, Jiang B, Zhang Z, Wang L, Jiang Y, Zou L, Liu X, Yu N, Mao X, Peng C, Liu S. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:21294-308. [PMID: 34470916 DOI: 10.18632/aging.203459] [Reference Citation Analysis]
414 Ko KL, To WP, Mak LY, Seto WK, Ning Q, Fung J, Lai CL, Yuen MF. A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. J Viral Hepat 2020;27:397-406. [PMID: 31755196 DOI: 10.1111/jvh.13237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
415 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
416 Wang R, Zang W, Hu B, Deng D, Ling X, Zhou H, Su M, Jiang J. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study. Technol Cancer Res Treat 2020;19:1533033820980785. [PMID: 33308056 DOI: 10.1177/1533033820980785] [Reference Citation Analysis]
417 Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, Seno H. Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E405. [PMID: 30909405 DOI: 10.3390/cancers11030405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
418 Okeke E, Mark Davwar P, Mullen B, Duguru M, Agbaji O, Sagay A, Murphy R, Hawkins C. The impact of HIV on hepatocellular cancer survival in Nigeria. Trop Med Int Health 2021;26:335-42. [PMID: 33244817 DOI: 10.1111/tmi.13532] [Reference Citation Analysis]
419 Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, Cheung RC, Nguyen MH. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1100-9. [PMID: 34469587 DOI: 10.1111/apt.16595] [Reference Citation Analysis]
420 Choi WM, Kim HJ, Jo AJ, Choi SH, Han S, Ko MJ, Lim YS. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int 2021. [PMID: 34242482 DOI: 10.1111/liv.15011] [Reference Citation Analysis]
421 Qi T, Dong Y, Gao Z, Xu J. Research Progress on the Anti-Cancer Molecular Mechanisms of Huaier. Onco Targets Ther 2020;13:12587-99. [PMID: 33335400 DOI: 10.2147/OTT.S281328] [Reference Citation Analysis]
422 Tokushima Y, Tago M, Tokushima M, Katsuki NE, Iwane S, Eguchi Y, Yamashita SI. Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. Int J Gen Med 2020;13:743-50. [PMID: 33061544 DOI: 10.2147/IJGM.S268857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
423 Li G, Xu W, Zhang L, Liu T, Jin G, Song J, Wu J, Wang Y, Chen W, Zhang C, Chen X, Ding Z, Zhu P, Zhang B. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine 2019;47:128-41. [PMID: 31492561 DOI: 10.1016/j.ebiom.2019.08.064] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
424 Baumeister SE, Schlesinger S, Aleksandrova K, Jochem C, Jenab M, Gunter MJ, Overvad K, Tjønneland A, Boutron-ruault M, Carbonnel F, Fournier A, Kühn T, Kaaks R, Pischon T, Boeing H, Trichopoulou A, Bamia C, La Vecchia C, Masala G, Panico S, Fasanelli F, Tumino R, Grioni S, Bueno de Mesquita B, Vermeulen R, May AM, Borch KB, Oyeyemi SO, Ardanaz E, Rodríguez-barranco M, Dolores Chirlaque López M, Felez-nobrega M, Sonestedt E, Ohlsson B, Hemmingsson O, Werner M, Perez-cornago A, Ferrari P, Stepien M, Freisling H, Tsilidis KK, Ward H, Riboli E, Weiderpass E, Leitzmann MF. Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. Journal of Hepatology 2019;70:885-92. [DOI: 10.1016/j.jhep.2018.12.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
425 Dantas E, Matos D, Coelho M, Sequeira C, Cardoso C, Oliveira AP. Hepatocellular Carcinoma with Atrial Extension: A Case Report. GE Port J Gastroenterol 2021;28:360-3. [PMID: 34604468 DOI: 10.1159/000511643] [Reference Citation Analysis]
426 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Zhou W, Fang D, He Y, Wei J. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. J Gastrointest Oncol 2021;12:1117-31. [PMID: 34295561 DOI: 10.21037/jgo-21-259] [Reference Citation Analysis]
428 Dong JJ, Ying L, Shi KQ. Expression of the Wnt ligands gene family and its relationship to prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:34. [PMID: 30814912 DOI: 10.1186/s12935-019-0743-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
429 Mashiko T, Masuoka Y, Nakano A, Tsuruya K, Hirose S, Hirabayashi K, Kagawa T, Nakagohri T. Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report. World J Gastroenterol 2020; 26(42): 6698-6705 [PMID: 33268957 DOI: 10.3748/wjg.v26.i42.6698] [Reference Citation Analysis]
430 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
431 Nankya-Mutyoba J, Aizire J, Makumbi F, Atuyambe L, Ocama P, Kirk GD. Correlates of hepatitis B awareness and disease-specific knowledge among pregnant women in Northern and Central Uganda: a cross-sectional study. Hepatol Med Policy 2018;3:14. [PMID: 30598844 DOI: 10.1186/s41124-018-0043-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
432 Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun 2018;2:747-59. [PMID: 29881825 DOI: 10.1002/hep4.1182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
433 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
434 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Reference Citation Analysis]
435 Redd Bowman KE, Lu P, Vander Mause ER, Lim CS. Advances in delivery vectors for gene therapy in liver cancer. Therapeutic Delivery 2020;11:833-50. [DOI: 10.4155/tde-2019-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
436 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
437 Merchante N, Rodríguez-Fernández M, Figueruela B, Rodríguez-Arrondo F, Revollo B, Ibarra S, Téllez F, Merino E, Montero-Alonso M, Galindo MJ, Rivero-Juárez A, Santos IL, Delgado-Fernández M, García-Deltoro M, Vera-Méndez FJ, García MA, Aguirrebengoa K, Portu J, Ríos-Villegas MJ, Villalobos M, Alemán-Valls MR, Mínguez C, Galera C, Macías J, Pineda JA; GEHEP-002 Study Group. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. AIDS 2020;34:1497-507. [PMID: 32675563 DOI: 10.1097/QAD.0000000000002578] [Reference Citation Analysis]
438 Nikolova-Karakashian M. Sphingolipids at the Crossroads of NAFLD and Senescence. Adv Cancer Res 2018;140:155-90. [PMID: 30060808 DOI: 10.1016/bs.acr.2018.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
439 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
440 Pian L, Huang X, Zhao M, Zhang Y, Qin C, Zhang J, Zhang J, Wang Q. Leucine-rich repeat and sterile alpha motif containing 1 promotes the oncogenic growth of human hepatocellular carcinoma cells. Cancer Cell Int 2019;19:255. [PMID: 31592239 DOI: 10.1186/s12935-019-0976-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
442 Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers (Basel) 2021;13:2899. [PMID: 34200529 DOI: 10.3390/cancers13122899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
443 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
444 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
445 Ha SY, Choi S, Park S, Kim JM, Choi GS, Joh JW, Park CK. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma. Virchows Arch 2020;477:807-16. [PMID: 32483662 DOI: 10.1007/s00428-020-02841-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
446 Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res 2019;5:42. [PMID: 31867441 DOI: 10.20517/2394-5079.2019.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
447 Wang W, Wang C, Xu H, Gao Y. Aldehyde Dehydrogenase, Liver Disease and Cancer. Int J Biol Sci 2020;16:921-34. [PMID: 32140062 DOI: 10.7150/ijbs.42300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
448 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
449 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
450 Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70:674-683. [PMID: 30543829 DOI: 10.1016/j.jhep.2018.12.001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 30.8] [Reference Citation Analysis]
451 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
452 Wang JH, Li WF, Yong CC, Liu YW, Lu SN, Wang CC. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep 2021;11:6041. [PMID: 33723365 DOI: 10.1038/s41598-021-85431-y] [Reference Citation Analysis]
453 Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. GSK-3 in liver diseases: Friend or foe? Biochim Biophys Acta Mol Cell Res 2020;1867:118743. [PMID: 32417256 DOI: 10.1016/j.bbamcr.2020.118743] [Reference Citation Analysis]
454 Shan QL, Chen NN, Meng GZ, Qu F. Overexpression of lncRNA MT1JP Mediates Apoptosis and Migration of Hepatocellular Carcinoma Cells by Regulating miR-24-3p. Cancer Manag Res 2020;12:4715-24. [PMID: 32606962 DOI: 10.2147/CMAR.S249582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Reference Citation Analysis]
456 Huang YY, Jiang HX, Shi QY, Qiu X, Wei X, Zhang XL, Qin SY. miR-145 Inhibits Th9 Cell Differentiation by Suppressing Activation of the PI3K/Akt/mTOR/p70S6K/HIF-1α Pathway in Malignant Ascites from Liver Cancer. Onco Targets Ther 2020;13:3789-800. [PMID: 32440147 DOI: 10.2147/OTT.S245346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
458 Li X, Lin J, Pan Y, Cui P, Xia J. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211041425. [PMID: 34866477 DOI: 10.1177/15330338211041425] [Reference Citation Analysis]
459 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
460 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
461 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
462 Noonan A, Pawlik TM. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs 2019;28:941-9. [DOI: 10.1080/13543784.2019.1677606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
463 Baudoin M, Woode ME, Nishimwe ML, Lemoine M, Sylla B, Kouanfack C, Moh R, Seydi M, Rouveau N, Attia A, Lacombe K, Boyer S. Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa. Liver Int 2020;40:2643-54. [PMID: 32687669 DOI: 10.1111/liv.14613] [Reference Citation Analysis]
464 Shim JH. Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? Clin Mol Hepatol 2020;26:183-4. [PMID: 32160729 DOI: 10.3350/cmh.2020.0042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
465 Tucker RD, Ciofoaia V, Nadella S, Gay MD, Cao H, Huber M, Safronenka A, Shivapurkar N, Kallakury B, Kruger AJ, Kroemer AHK, Smith JP. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Dig Dis Sci 2020;65:189-203. [PMID: 31297627 DOI: 10.1007/s10620-019-05722-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
466 Sun JY, Zhang XY, Cao YZ, Zhou X, Gu J, Mu XX. Diagnostic and prognostic value of circular RNAs in hepatocellular carcinoma. J Cell Mol Med 2020;24:5438-45. [PMID: 32281724 DOI: 10.1111/jcmm.15258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
467 Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019;9:19. [PMID: 30719425 DOI: 10.3389/fonc.2019.00019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
468 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Hu XX, Feng J, Huang XW, Lu PZ, Wang ZX, Dai HQ, Deng JH, Ye XP, Peng T, Hooi SC, Zhou J, Lu GD. Histone deacetylases up-regulate C/EBPα expression through reduction of miR-124-3p and miR-25 in hepatocellular carcinoma. Biochem Biophys Res Commun 2019;514:1009-16. [PMID: 31092334 DOI: 10.1016/j.bbrc.2019.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
470 Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:513-27. [PMID: 34104640 DOI: 10.2147/JHC.S268288] [Reference Citation Analysis]
471 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open 2019;9:e026703. [PMID: 31061041 DOI: 10.1136/bmjopen-2018-026703] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
472 Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS. Precision oncology in liver cancer. Ann Transl Med 2018;6:285. [PMID: 30105235 DOI: 10.21037/atm.2018.06.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
473 Guo C, Zou X, Hong Z, Sun J, Xiao W, Sun K, Li X, Shen Y, Liang T, Bai X. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. HPB (Oxford) 2021:S1365-182X(21)00043-5. [PMID: 33715958 DOI: 10.1016/j.hpb.2021.02.006] [Reference Citation Analysis]
474 Yang C, Wang S, Ruan H, Li B, Cheng Z, He J, Zuo Q, Yu C, Wang H, Lv Y, Gu D, Jin G, Yao M, Qin W, Jin H. Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:918-26. [PMID: 30854098 DOI: 10.7150/jca.27226] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
475 Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology. 2019;156:1862-1876.e9. [PMID: 30711630 DOI: 10.1053/j.gastro.2019.01.251] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
476 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Reference Citation Analysis]
477 Sonntag R, Penners C, Kohlhepp M, Haas U, Lambertz D, Kroh A, Cramer T, Ticconi F, Costa IG, Tacke F, Gassler N, Trautwein C, Liedtke C. Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers (Basel) 2021;13:5680. [PMID: 34830835 DOI: 10.3390/cancers13225680] [Reference Citation Analysis]
478 Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 2021;10:575. [PMID: 33807929 DOI: 10.3390/cells10030575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
479 Shabangu CS, Huang JF, Hsiao HH, Yu ML, Chuang WL, Wang SC. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. Int J Mol Sci 2020;21:E3732. [PMID: 32466319 DOI: 10.3390/ijms21103732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
480 Yao C, Ng E, Wang SX. An automated and mobile magnetoresistive biosensor system for early hepatocellular carcinoma diagnosis. Biosens Bioelectron 2022;202:113982. [PMID: 35033828 DOI: 10.1016/j.bios.2022.113982] [Reference Citation Analysis]
481 Xu JH, Guan YJ, Qiu ZD, Zhang X, Zi LL, Zhou Y, Chen C, Yu J, Zhang YC, Wang WX. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma. Oxid Med Cell Longev 2021;2021:6485871. [PMID: 34795841 DOI: 10.1155/2021/6485871] [Reference Citation Analysis]
482 Tian Y, Li T, Qi S, Alhourani H, Luo B, Chenqin J, Fu Q, Peng Y, Wu J. The impact of metabolic syndrome (MetS) on surgical outcome for patients with mostly HBV-related hepatocellular carcinoma (HCC) underwent hepatectomy. J Surg Oncol 2020. [PMID: 32502302 DOI: 10.1002/jso.26055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
483 Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, Cheng LL. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol 2019;16:339-62. [PMID: 31092915 DOI: 10.1038/s41585-019-0185-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 20.5] [Reference Citation Analysis]
484 Thomas CE, Luu HN, Wang R, Xie G, Adams-Haduch J, Jin A, Koh WP, Jia W, Behari J, Yuan JM. Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers (Basel) 2021;13:2648. [PMID: 34071196 DOI: 10.3390/cancers13112648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Honap S, Oben JA. Fat and Hidden Liver Cancer. Clin Liver Dis (Hoboken) 2021;17:49-52. [PMID: 33680434 DOI: 10.1002/cld.1011] [Reference Citation Analysis]
486 Park JS, Ma H, Roh YS. Ubiquitin pathways regulate the pathogenesis of chronic liver disease. Biochem Pharmacol 2021;193:114764. [PMID: 34529948 DOI: 10.1016/j.bcp.2021.114764] [Reference Citation Analysis]
487 Huang S, Li D, Zhuang L, Sun L, Wu J. Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:690151. [PMID: 34307456 DOI: 10.3389/fmolb.2021.690151] [Reference Citation Analysis]
488 Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, Zeng HY, Qiu SJ, Cao Y, Fan J, Zhou J, Yang XR. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med 2021;11:e335. [PMID: 33634982 DOI: 10.1002/ctm2.335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Schnabl B, Arteel GE, Stickel F, Hengstler J, Vartak N, Ghallab A, Dooley S, Li Y, Schwabe RF. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Z Gastroenterol 2022;60:36-44. [PMID: 35042252 DOI: 10.1055/a-1714-9330] [Reference Citation Analysis]
490 Tateishi R, Koike K. Changing etiology of hepatocellular carcinoma. J Gastroenterol 2020;55:125-6. [PMID: 31473829 DOI: 10.1007/s00535-019-01622-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
491 Huang CF, Yu ML. Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter? Clin Mol Hepatol 2019;25:168-71. [PMID: 30739433 DOI: 10.3350/cmh.2018.1014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
492 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
493 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
494 Ocker M, Neureiter D. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Rev Gastroenterol Hepatol 2021;15:111-3. [PMID: 32985933 DOI: 10.1080/17474124.2021.1829472] [Reference Citation Analysis]
495 Liu X, Meng J, Xu H, Niu J. Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e15414. [PMID: 31027143 DOI: 10.1097/MD.0000000000015414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
496 Centonze L, Di Sandro S, Lauterio A, De Carlis R, Sgrazzutti C, Ciulli C, Vella I, Vicentin I, Incarbone N, Bagnardi V, Vanzulli A, De Carlis L. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters. Transpl Int 2021;34:1712-21. [PMID: 34448275 DOI: 10.1111/tri.13983] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
497 Baumeister SE, Leitzmann MF, Linseisen J, Schlesinger S. Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis. J Natl Cancer Inst 2019;111:1142-51. [PMID: 31168582 DOI: 10.1093/jnci/djz111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
498 Gong Y, Li D, Li L, Yang J, Ding H, Zhang C, Wen G, Wu C, Fang Z, Hou S, Yang Y. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis. Food and Chemical Toxicology 2021;147:111912. [DOI: 10.1016/j.fct.2020.111912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
499 Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
500 Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol 2020;54:459-67. [PMID: 30672817 DOI: 10.1097/MCG.0000000000001172] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
501 Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today 2021;26:1539-46. [PMID: 33561464 DOI: 10.1016/j.drudis.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
502 Radosa CG, Radosa JC, Grosche-Schlee S, Zöphel K, Plodeck V, Kühn JP, Kotzerke J, Hoffmann RT. Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice. Cardiovasc Intervent Radiol 2019;42:405-12. [PMID: 30603976 DOI: 10.1007/s00270-018-2133-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
503 Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Reference Citation Analysis]
504 Chen YS, Yang SY, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med 2021;11:1261. [PMID: 34945733 DOI: 10.3390/jpm11121261] [Reference Citation Analysis]
505 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
506 Cagnin M, Biasiolo A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Sci Rep 2019;9:20126. [PMID: 31882893 DOI: 10.1038/s41598-019-56633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
507 Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology. 2020;71:1910-1922. [PMID: 31610027 DOI: 10.1002/hep.30988] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
508 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
509 Paik JM, Younossi Y, Henry L, Mishra A, Younossi ZM. Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. Gastroenterology 2021;160:1845-1846.e3. [PMID: 33421516 DOI: 10.1053/j.gastro.2020.11.057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
510 Liu B, Yang G, Wang X, Liu J, Lu Z, Wang Q, Xu B, Liu Z, Li J. CircBACH1 (hsa_circ_0061395) promotes hepatocellular carcinoma growth by regulating p27 repression via HuR. J Cell Physiol 2020;235:6929-41. [PMID: 32003018 DOI: 10.1002/jcp.29589] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
511 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
512 Li TE, Zhang Z, Wang Y, Xu D, Dong J, Zhu Y, Wang Z. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:2866-76. [PMID: 33854587 DOI: 10.7150/jca.54408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Smith WH, Law AS, Hulkower M, McGee HM, Lehrer EJ, Schwartz M, Taouli B, Sung M, Buckstein M. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncol 2020;59:940-3. [PMID: 32441551 DOI: 10.1080/0284186X.2020.1769860] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
514 Shwartz A, Goessling W, Yin C. Macrophages in Zebrafish Models of Liver Diseases. Front Immunol 2019;10:2840. [PMID: 31867007 DOI: 10.3389/fimmu.2019.02840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
515 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
516 Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer 2021;21:569. [PMID: 34006248 DOI: 10.1186/s12885-021-08124-9] [Reference Citation Analysis]
517 Sun M, Shang P, Bai J, Li S, Li M. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal 2021;35:e23633. [PMID: 33099812 DOI: 10.1002/jcla.23633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
518 Zhang B, Wu Q, Guo X. Comments on the article "The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis". Int J Surg 2018;58:1-2. [PMID: 30149184 DOI: 10.1016/j.ijsu.2018.06.039] [Reference Citation Analysis]
519 Kimanya ME, Routledge MN, Mpolya E, Ezekiel CN, Shirima CP, Gong YY. Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data. PLoS One 2021;16:e0247281. [PMID: 33705417 DOI: 10.1371/journal.pone.0247281] [Reference Citation Analysis]
520 Stockdale AJ, Mitambo C, Everett D, Geretti AM, Gordon MA. Epidemiology of hepatitis B, C and D in Malawi: systematic review. BMC Infect Dis 2018;18:516. [PMID: 30314448 DOI: 10.1186/s12879-018-3428-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
521 Wang Z, Zhao K, Zhang Y, Duan X, Zhao Y. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. Pharm Res 2019;36:145. [PMID: 31396764 DOI: 10.1007/s11095-019-2669-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
522 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
523 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One 2018;13:e0196301. [PMID: 29689073 DOI: 10.1371/journal.pone.0196301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
524 Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 2021;30:1643-51. [PMID: 34155064 DOI: 10.1158/1055-9965.EPI-21-0183] [Reference Citation Analysis]
525 Chan LL, Chan SL. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2021;26:39-52. [PMID: 33724135 DOI: 10.1080/14728214.2021.1902503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
526 Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. Clin Gastroenterol Hepatol 2020;18:242-248.e5. [PMID: 31042582 DOI: 10.1016/j.cgh.2019.04.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
527 Sepulveda-Villegas M, Roman S, Rivera-Iñiguez I, Ojeda-Granados C, Gonzalez-Aldaco K, Torres-Reyes LA, Jose-Abrego A, Panduro A. High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. PLoS One 2019;14:e0208926. [PMID: 30608932 DOI: 10.1371/journal.pone.0208926] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
528 Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: Innovations and expectations. World J Gastroenterol 2022; 28(5): 517-531 [DOI: 10.3748/wjg.v28.i5.517] [Reference Citation Analysis]
529 Chen X, Meng F, Xiong H, Zou Y. Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis. Front Oncol 2021;11:600027. [PMID: 33777744 DOI: 10.3389/fonc.2021.600027] [Reference Citation Analysis]
530 Liu L, Wang Y, Zhang J, Wang C, Li Y, Dai W, Piao C, Liu J, Yu H, Li X, Wang Y, Liu J. Probiotics in treating with alcoholic liver disease and nonalcoholic fatty liver disease. Food Reviews International. [DOI: 10.1080/87559129.2021.1967380] [Reference Citation Analysis]
531 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
532 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
533 Mu XM, Wang W, Jiang YY, Feng J. Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. Int J Environ Res Public Health 2020;17:E3108. [PMID: 32365650 DOI: 10.3390/ijerph17093108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
534 Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol 2021;14:79. [PMID: 33758660 DOI: 10.3892/mco.2021.2241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020; 12(12): 1239-1257 [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
536 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
537 Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. Hepatology. 2019;69:1983-1994. [PMID: 30153338 DOI: 10.1002/hep.30233] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 13.7] [Reference Citation Analysis]
538 Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat 2020;27:671-9. [PMID: 32050037 DOI: 10.1111/jvh.13276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
539 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Reference Citation Analysis]
540 Wang H, Yang B, Cai X, Cheng X, Shen N, Liu L, Li J, Wang Y, He H, Ying P, Li B, Lu Z, Yang N, Wang X, Zhang F, Li Y, Wang W, Ning C, Zhu Y, Chang J, Miao X, Tian J, Zhong R. Hepatocellular carcinoma risk variant modulates lncRNA HLA-DQB1-AS1 expression via a long-range enhancer-promoter interaction. Carcinogenesis 2021;42:1347-56. [PMID: 34665859 DOI: 10.1093/carcin/bgab095] [Reference Citation Analysis]
541 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
542 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
543 Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res 2019;162:136-41. [PMID: 30599173 DOI: 10.1016/j.antiviral.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
544 Sinharay R, Grant AJ, Rivett L, Blackwell R, Mells G, Gelson W. Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. GastroHep 2021;3:80-7. [PMID: 33821150 DOI: 10.1002/ygh2.443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
546 Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, Tan AT, Aleman S, Sandberg JK, Bertoletti A, Sällberg Chen M. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Rep 2021;3:100318. [PMID: 34377970 DOI: 10.1016/j.jhepr.2021.100318] [Reference Citation Analysis]
547 Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
548 Yang CJ, Wang CK, Fang YD, Wang JY, Su FC, Tsai HM, Lin YJ, Tsai HW, Yeh LR. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. PLoS One 2021;16:e0255605. [PMID: 34375365 DOI: 10.1371/journal.pone.0255605] [Reference Citation Analysis]
549 Akhtar S. Preoperative evaluation of geriatric patients undergoing liver transplantation. Curr Opin Anaesthesiol 2022;35:96-104. [PMID: 34878418 DOI: 10.1097/ACO.0000000000001084] [Reference Citation Analysis]
550 Peng YS, Lin JR, Cheng BH, Ho C, Lin YH, Shen CH, Tsai MH. Incidence and relative risk for developing cancers in women with gestational diabetes mellitus: a nationwide cohort study in Taiwan. BMJ Open 2019;9:e024583. [PMID: 30796123 DOI: 10.1136/bmjopen-2018-024583] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
551 Yang J, Li Y, Liu Q, Li L, Feng A, Wang T, Zheng S, Xu A, Lyu J. Brief introduction of medical database and data mining technology in big data era. J Evid Based Med 2020;13:57-69. [PMID: 32086994 DOI: 10.1111/jebm.12373] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
552 Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Reference Citation Analysis]
553 Wang Y, Yan P, Fu T, Yuan J, Yang G, Liu Y, Zhang ZJ. The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. Diabetes Metab 2020;46:461-71. [PMID: 32097717 DOI: 10.1016/j.diabet.2020.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
554 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
555 Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, El-Desouky ED, Abd Elmageed ZY, Abdel-Wahab AA. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019;65:45-52. [PMID: 30653948 DOI: 10.1016/j.clinbiochem.2019.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
556 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
557 Cai W, He B, Hu M, Zhang W, Xiao D, Yu H, Song Q, Xiang N, Yang J, He S, Huang Y, Huang W, Jia F, Fang C. A radiomics-based nomogram for the preoperative prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. Surg Oncol. 2019;28:78-85. [PMID: 30851917 DOI: 10.1016/j.suronc.2018.11.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
558 Vo TK, Ta QTH, Chu QT, Nguyen TT, Vo VG. Anti-Hepatocellular-Cancer Activity Exerted by β-Sitosterol and β-Sitosterol-Glucoside from Indigofera zollingeriana Miq. Molecules 2020;25:E3021. [PMID: 32630623 DOI: 10.3390/molecules25133021] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
559 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
560 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
561 Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol 2018;15:536-54. [DOI: 10.1038/s41575-018-0033-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 17.5] [Reference Citation Analysis]
562 Qiu YA, Xiong J, Fu Q, Dong Y, Liu M, Peng M, Jin W, Zhou L, Xu X, Huang X, Fu A, Xu G, Tu G, Yu T. GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma. Front Oncol 2021;11:638171. [PMID: 33767999 DOI: 10.3389/fonc.2021.638171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021;510:48-58. [PMID: 33891996 DOI: 10.1016/j.canlet.2021.04.008] [Reference Citation Analysis]
564 Allaire M, El Hajj W, Brichler S, Diallo K, Fanica D, Blaise L, Nkontchou G, Grando V, Arbadi F, Nahon P, Ziol M, Nault JC, Ganne-Carrié N. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West. Clin Res Hepatol Gastroenterol 2021;45:101436. [PMID: 32418851 DOI: 10.1016/j.clinre.2020.03.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
565 Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PMID: 31319016 DOI: 10.1111/liv.14194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
566 Su C, Jin C, Han J, Hu X, Shi D, Meng F. Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol 2020;32:838-43. [PMID: 31725029 DOI: 10.1097/MEG.0000000000001589] [Reference Citation Analysis]
567 Liu Z, Suo C, Mao X, Jiang Y, Jin L, Zhang T, Chen X. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer 2020;126:2267-78. [PMID: 32201944 DOI: 10.1002/cncr.32789] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
568 Ali HS, Boshra MS, El Meteini MS, Shafei AE, Matboli M. lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma. Genomics 2020;112:3306-14. [PMID: 32544548 DOI: 10.1016/j.ygeno.2020.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
569 Keller SB, Suo D, Wang YN, Kenerson H, Yeung RS, Averkiou MA. Image-Guided Treatment of Primary Liver Cancer in Mice Leads to Vascular Disruption and Increased Drug Penetration. Front Pharmacol 2020;11:584344. [PMID: 33101038 DOI: 10.3389/fphar.2020.584344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
570 Nguyen L, Chapel S, Tran BD, Lacy S. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J Pharmacokinet Pharmacodyn 2019;46:577-89. [PMID: 31637577 DOI: 10.1007/s10928-019-09659-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
571 Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2524-2538 [PMID: 31171895 DOI: 10.3748/wjg.v25.i20.2524] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
572 Hang Pham TT, Le TX, Nguyen DT, Luu CM, Truong BD, Tran PD, Toy M, Bozkurt S, So S. Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam. PLoS One 2019;14:e0223733. [PMID: 31609983 DOI: 10.1371/journal.pone.0223733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
573 Rasche A, Sander AL, Corman VM, Drexler JF. Evolutionary biology of human hepatitis viruses. J Hepatol 2019;70:501-20. [PMID: 30472320 DOI: 10.1016/j.jhep.2018.11.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
574 Doan HV, Sritangos P, Iyara R, Chudapongse N. Chrysophyllum cainito stem bark extract induces apoptosis in Human hepatocarcinoma HepG2 cells through ROS-mediated mitochondrial pathway. PeerJ 2020;8:e10168. [PMID: 33088629 DOI: 10.7717/peerj.10168] [Reference Citation Analysis]
575 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
576 Qiu R, Murata S, Cheng C, Mori A, Nie Y, Mikami S, Hasegawa S, Tadokoro T, Okamoto S, Taniguchi H. A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment. Cancers (Basel) 2021;13:3997. [PMID: 34439154 DOI: 10.3390/cancers13163997] [Reference Citation Analysis]
577 Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Reference Citation Analysis]
578 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
579 Sutton TL, Billingsley KG, Walker BS, Fung AW, Maynard E, Enestvedt CK, Dewey EN, Brinkerhoff BT, Lopez CD, Orloff SL, Mayo SC. Detection of Tumor Multifocality in Resectable Intrahepatic Cholangiocarcinoma: Defining the Optimal Pre-operative Imaging Modality. J Gastrointest Surg 2021. [PMID: 33565011 DOI: 10.1007/s11605-021-04911-8] [Reference Citation Analysis]
580 Min X, Wen J, Zhao L, Wang K, Li Q, Huang G, Liu J, Zhao X. Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma. Mol Oncol 2018;12:1480-97. [PMID: 30004626 DOI: 10.1002/1878-0261.12357] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
581 Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3:100304. [PMID: 34136776 DOI: 10.1016/j.jhepr.2021.100304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
582 Devictor J, Leclercq A, Hazo JB, Burnet E, Jovic L, Bouattour M, Ganne-Carrié N. Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey. Clin Res Hepatol Gastroenterol 2021;45:101650. [PMID: 33609787 DOI: 10.1016/j.clinre.2021.101650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Kim KW, Choi JI. Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1665. [PMID: 34574006 DOI: 10.3390/diagnostics11091665] [Reference Citation Analysis]
584 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Artzner C, Bitzer M, Horger M, Grözinger G. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. Eur J Radiol 2021;140:109768. [PMID: 33991970 DOI: 10.1016/j.ejrad.2021.109768] [Reference Citation Analysis]
585 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
586 Nie JJ, Liu Y, Qi Y, Zhang N, Yu B, Chen DF, Yang M, Xu FJ. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. J Control Release 2021;333:362-73. [PMID: 33785418 DOI: 10.1016/j.jconrel.2021.03.030] [Reference Citation Analysis]
587 Mwachiro M, Topazian HM, Kayamba V, Mulima G, Ogutu E, Erkie M, Lenga G, Mutie T, Mukhwana E, Desalegn H, Berhe R, Meshesha BR, Kaimila B, Kelly P, Fleischer D, Dawsey SM, Topazian MD. Gastrointestinal endoscopy capacity in Eastern Africa. Endosc Int Open 2021;9:E1827-36. [PMID: 34790551 DOI: 10.1055/a-1551-3343] [Reference Citation Analysis]
588 Liu H, Wu Q, Cao J, Wang X, Song Y, Mei W, Wang X. A phenanthroline derivative enhances radiosensitivity of hepatocellular carcinoma cells by inducing mitochondria-dependent apoptosis. European Journal of Pharmacology 2019;843:285-91. [DOI: 10.1016/j.ejphar.2018.10.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
589 Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8. [PMID: 32847986 DOI: 10.1136/jitc-2020-000987] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
590 Shen Y, Xiong W, Gu Q, Zhang Q, Yue J, Liu C, Wang D. Multi-Omics Integrative Analysis Uncovers Molecular Subtypes and mRNAs as Therapeutic Targets for Liver Cancer. Front Med (Lausanne) 2021;8:654635. [PMID: 34109194 DOI: 10.3389/fmed.2021.654635] [Reference Citation Analysis]
591 Sung K, Johnston MP, Lee MY, Byrne CD. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. Liver Int 2020;40:1303-15. [DOI: 10.1111/liv.14416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
592 Gu J, Zhang E, Liang B, Zhang Z, Chen X, Xiong M, Huang Z. Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function. Ann Surg Oncol 2021;28:4227-35. [PMID: 33452603 DOI: 10.1245/s10434-020-09557-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
593 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
594 Kim YY, An C, Kim DY, Aljoqiman KS, Choi JY, Kim MJ. Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography 2019;38:311-20. [PMID: 31079440 DOI: 10.14366/usg.18051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
595 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
596 Zhang H, Chen X, Yuan Y. Investigation of the miRNA and mRNA Coexpression Network and Their Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8726567. [PMID: 33274225 DOI: 10.1155/2020/8726567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
597 Feng Q, Zhang H, Nie X, Li Y, Chen W, Wang Y. miR-149* Suppresses Liver Cancer Progression by Down-Regulating Tumor Necrosis Factor Receptor 1–Associated Death Domain Protein Expression. The American Journal of Pathology 2020;190:469-83. [DOI: 10.1016/j.ajpath.2019.10.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
598 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
599 Chen S, Jiang T. Preoperative noninvasive assessment for liver fibrosis in hepatocellular carcinoma patients with chronic hepatitis B: Comparison of two-dimensional shear-wave elastography with serum liver fibrosis models. Eur J Radiol 2020;133:109386. [PMID: 33160197 DOI: 10.1016/j.ejrad.2020.109386] [Reference Citation Analysis]
600 Dakurah OB, Tamandjou CRT, Zunza M, Preiser W, Maponga TG. Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. BMC Cancer 2021;21:715. [PMID: 34144696 DOI: 10.1186/s12885-021-08426-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
601 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Du H, Bennett D, Bian Z, Chen Y, Yang L, Turnbull I, Wang H, Li H, Holmes MV, Chen J, Chen Z, Li L. Association of physical activity with risk of hepatobiliary diseases in China: a prospective cohort study of 0.5 million people. Br J Sports Med 2021;55:1024-33. [PMID: 32826226 DOI: 10.1136/bjsports-2020-102174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
602 Hirai M, Kinugasa H, Nouso K, Yamamoto S, Terasawa H, Onishi Y, Oyama A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Okada H. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. J Gastroenterol Hepatol. 2020;. [PMID: 32830343 DOI: 10.1111/jgh.15227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
603 Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res 2020;6:5. [PMID: 32582865 DOI: 10.20517/2394-5079.2019.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
604 Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 2019;64:910-7. [DOI: 10.1007/s10620-019-05537-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 28.7] [Reference Citation Analysis]
605 Pohlman RM, Hinshaw JL, Ziemlewicz TJ, Lubner MG, Wells SA, Lee FT Jr, Alexander ML, Wergin KL, Varghese T. Differential Imaging of Liver Tumors before and after Microwave Ablation with Electrode Displacement Elastography. Ultrasound Med Biol 2021;47:2138-56. [PMID: 34011451 DOI: 10.1016/j.ultrasmedbio.2021.03.027] [Reference Citation Analysis]
606 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
607 Chiang MF, Tseng TK, Shih CW, Yang TH, Wu SY. Clinical and contrast-enhanced image features in the prediction model for the detection of small hepatocellular carcinomas. J Cancer 2020;11:7166-75. [PMID: 33193879 DOI: 10.7150/jca.47245] [Reference Citation Analysis]
608 Cho MJ, An C, Aljoqiman KS, Choi JY, Lim JS, Park MS, Rhee H, Kim MJ. Diagnostic performance of Liver Imaging Reporting and Data System in patients at risk of both hepatocellular carcinoma and metastasis. Abdom Radiol (NY) 2020;45:3789-99. [PMID: 32440900 DOI: 10.1007/s00261-020-02581-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
609 Miguet M, Adam JP, Blanc JF, Lapuyade B, Bernard P, Buscail E, Neau-Cransac M, Vendrely V, Laurent C, Chiche L. Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed? J Visc Surg 2019;156:217-27. [PMID: 31203872 DOI: 10.1016/j.jviscsurg.2018.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
610 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
611 Paul SB, Sahu P, Sreenivas V, Nadda N, Gamanagatti SR, Nayak B, Shalimar S, Acharya SK. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. Scand J Gastroenterol 2019;54:1132-7. [PMID: 31483691 DOI: 10.1080/00365521.2019.1660403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
612 Tian S, Li J, Guo Y, Dong W, Zheng X. Expression Status and Prognostic Significance of Gamma-Glutamyl Transpeptidase Family Genes in Hepatocellular Carcinoma. Front Oncol 2021;11:731144. [PMID: 34513707 DOI: 10.3389/fonc.2021.731144] [Reference Citation Analysis]
613 Anugwom CM, Allaire M, Akbar SMF, Sultan A, Bollipo S, Mattos AZ, Debes JD. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021;7:23. [PMID: 33884303 DOI: 10.20517/2394-5079.2021.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
614 deLemos A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol 2020;11:e00139. [PMID: 32352723 DOI: 10.14309/ctg.0000000000000139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
615 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Reference Citation Analysis]
616 Liu ZL, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol 2021;13:17588359211018026. [PMID: 34104226 DOI: 10.1177/17588359211018026] [Reference Citation Analysis]
617 Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2020;36:235-43. [PMID: 31631714 DOI: 10.1080/03007995.2019.1683817] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
618 Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
619 Luong AB, Do HQ, Tarchi P, Bonazza D, Bottin C, Cabral LKD, Tran LDC, Doan TPT, Crocè LS, Pham HLT, Tiribelli C, Sukowati CHC. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells 2020;9:E2672. [PMID: 33322687 DOI: 10.3390/cells9122672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
620 Hsiao CY, Yang PC, Huang KW. Linear radiofrequency ablation using dual switching-control mode achieves rapid and bloodless liver resection, an experimental research. Int J Hyperthermia 2021;38:357-62. [PMID: 33641575 DOI: 10.1080/02656736.2021.1892215] [Reference Citation Analysis]
621 Liu Y, Li Y, Wang X, Huang Y, Zhang Q, Shi K, Ran C, Hou J, Wang X. Fufang Banmao Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3-4 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment. J Altern Complement Med 2020;26:956-65. [PMID: 32614605 DOI: 10.1089/acm.2019.0334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
622 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Reference Citation Analysis]
623 Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T. Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:5282. [PMID: 34771452 DOI: 10.3390/cancers13215282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
624 Fattahi N, Rezaei N, Asadi-Lari M, Yousefi M, Madadi Z, Gohari K, Sheidaei A, Mohammadi E, Rezaei N, Parsaeian M, Kompani F, Farzadfar F. Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis. PLoS One 2021;16:e0245468. [PMID: 33481849 DOI: 10.1371/journal.pone.0245468] [Reference Citation Analysis]
625 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
626 Zhao HQ, Dong BL, Zhang M, Dong XH, He Y, Chen SY, Wu B, Yang XJ. Increased KIF21B expression is a potential prognostic biomarker in hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(3): 276-288 [PMID: 32206178 DOI: 10.4251/wjgo.v12.i3.276] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
627 Hewitt DB, Rahnemai-Azar AA, Pawlik TM. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opin Investig Drugs 2021;30:827-35. [PMID: 34102935 DOI: 10.1080/13543784.2021.1940948] [Reference Citation Analysis]
628 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Reference Citation Analysis]
629 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
630 Luo B, Yun X, Li J, Fan R, Guo WW, Liu C, Lin YD, Ge YY, Zeng X, Bi SQ, Nong WX, Zhang QM, Xie XX. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Curr Med Sci 2020;40:719-28. [PMID: 32862383 DOI: 10.1007/s11596-020-2241-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
631 Lim YS. Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean J Gastroenterol 2021;78:284-8. [PMID: 34824186 DOI: 10.4166/kjg.2021.137] [Reference Citation Analysis]
632 Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel) 2019;11:E1078. [PMID: 31366113 DOI: 10.3390/cancers11081078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
633 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Reference Citation Analysis]
634 Pocha PV, Xie C, Pocha C. Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. Ann Transl Med 2021;9:2. [PMID: 33553295 DOI: 10.21037/atm-20-7534] [Reference Citation Analysis]
635 Hang Pham TT, Le TX, Nguyen DT, Luu CM, Truong BD, Tran PD, Toy M, So S. Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam. PLoS One 2019;14:e0208154. [PMID: 30969972 DOI: 10.1371/journal.pone.0208154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
636 Itoh S, Yoshizumi T, Mori M. Is sarcopenic obesity superior to sarcopenia as a predicting indicator in patients with hepatocellular carcinoma following hepatic resection? Hepatobiliary Surg Nutr 2020;9:202-4. [PMID: 32355679 DOI: 10.21037/hbsn.2019.09.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
637 Dahlgren D, Lennernäs H. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020;25:E2861. [PMID: 32575828 DOI: 10.3390/molecules25122861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
638 Yamamoto S, Kondo S. Oral chemotherapy for the treatment of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2018;19:993-1001. [DOI: 10.1080/14656566.2018.1479398] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
639 Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, Heinrich B, Yu SJ, Zhang Q, Wilson A, Shi ZD, Swenson R, Greten TF. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis 2018;9:620. [PMID: 29795111 DOI: 10.1038/s41419-018-0687-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
640 Du N, Ma J, Zhang Z, Zhou Y, Yang M, Zhang W, Luo J, Yan Z. Development of a Novel Endovascular Brachytherapy Stent: A Proof-of-concept Study. J Clin Transl Hepatol 2021;9:711-8. [PMID: 34722186 DOI: 10.14218/JCTH.2020.00128] [Reference Citation Analysis]
641 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
642 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
643 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
644 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
645 Gong X, Qin S. Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2018;7:466-74. [PMID: 30652091 DOI: 10.21037/hbsn.2018.11.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
646 So YJ, Frentzas S, Segelov E. Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC? Hepatobiliary Surg Nutr 2019;8:546-8. [PMID: 31673554 DOI: 10.21037/hbsn.2019.04.14] [Reference Citation Analysis]
647 Cao M, Ding C, Xia C, Li H, Sun D, He S, Chen W. Attributable deaths of liver cancer in China. Chin J Cancer Res 2021;33:480-9. [PMID: 34584373 DOI: 10.21147/j.issn.1000-9604.2021.04.05] [Reference Citation Analysis]
648 Paik JM, Mir S, Alqahtani SA, Younossi Y, Ong JP, Younossi ZM. Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. Hepatol Commun 2021. [PMID: 34558838 DOI: 10.1002/hep4.1707] [Reference Citation Analysis]
649 Azit NA, Sahran S, Voon Meng L, Subramaniam M, Mokhtar S, Mohammed Nawi A. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. PLoS One 2021;16:e0260675. [PMID: 34882716 DOI: 10.1371/journal.pone.0260675] [Reference Citation Analysis]
650 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
651 Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J 2019;7:850-8. [PMID: 31316789 DOI: 10.1177/2050640619840199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
652 Ogbo FA, Mathsyaraja S, Koti RK, Perz J, Page A. The burden of depressive disorders in South Asia, 1990-2016: findings from the global burden of disease study. BMC Psychiatry 2018;18:333. [PMID: 30326863 DOI: 10.1186/s12888-018-1918-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
653 Poláková L, Širc J, Hobzová R, Cocârță AI, Heřmánková E. Electrospun nanofibers for local anticancer therapy: Review of in vivo activity. Int J Pharm 2019;558:268-83. [PMID: 30611748 DOI: 10.1016/j.ijpharm.2018.12.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
654 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
655 Dawood AA, Saleh AA, Elbahr O, Gohar SF, Habieb MS. Inverse relationship between the level of miRNA 148a-3p and both TGF-β1 and FIB-4 in hepatocellular carcinoma. Biochem Biophys Rep 2021;27:101082. [PMID: 34355070 DOI: 10.1016/j.bbrep.2021.101082] [Reference Citation Analysis]
656 Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, Weiss MJ, He J, Philosophe B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight 2021;6:138197. [PMID: 34003798 DOI: 10.1172/jci.insight.138197] [Reference Citation Analysis]
657 Wang SM, Yang PW, Feng XJ, Zhu YW, Qiu FJ, Hu XD, Zhang SH. Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome. Front Oncol 2021;11:657665. [PMID: 33959508 DOI: 10.3389/fonc.2021.657665] [Reference Citation Analysis]
658 He F, Sha Y, Wang B. Relationship between alcohol consumption and the risks of liver cancer, esophageal cancer, and gastric cancer in China: Meta-analysis based on case-control studies. Medicine (Baltimore) 2021;100:e26982. [PMID: 34414976 DOI: 10.1097/MD.0000000000026982] [Reference Citation Analysis]
659 El-Garawani IM, El-Sabbagh SM, Abbas NH, Ahmed HS, Eissa OA, Abo-Atya DM, Khalifa SAM, El-Seedi HR. A newly isolated strain of Halomonas sp. (HA1) exerts anticancer potential via induction of apoptosis and G2/M arrest in hepatocellular carcinoma (HepG2) cell line. Sci Rep 2020;10:14076. [PMID: 32826930 DOI: 10.1038/s41598-020-70945-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
660 Kitsou K, Iliopoulou M, Spoulou V, Lagiou P, Magiorkinis G. Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review. Front Oncol 2021;11:687631. [PMID: 34778024 DOI: 10.3389/fonc.2021.687631] [Reference Citation Analysis]
661 Zhou X, Zhu A, Gu X, Xie G. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. Cell Oncol 2019;42:369-80. [DOI: 10.1007/s13402-019-00432-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
662 Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond) 2020;52:625-37. [PMID: 32644030 DOI: 10.1080/23744235.2020.1766104] [Reference Citation Analysis]
663 Sadiq AM, Mjemmas MG, Sadiq AM, Nkya GZ. Sarcomatoid hepatocellular carcinoma in a young African female. SAGE Open Med Case Rep 2021;9:2050313X211052452. [PMID: 34646567 DOI: 10.1177/2050313X211052452] [Reference Citation Analysis]
664 Hao YJ, Sun HB, Li HW, Chen BJ, Chen XL, Ma L, Li YL. Application of positive behavior management in patients after breast cancer surgery. World J Clin Cases 2020; 8(4): 689-699 [PMID: 32149053 DOI: 10.12998/wjcc.v8.i4.689] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
665 Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9:563-582. [PMID: 33083281 DOI: 10.1159/000508568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
666 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00215-9. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
667 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Chen XP, Huang ZY. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep 2021;11:16343. [PMID: 34381132 DOI: 10.1038/s41598-021-95835-5] [Reference Citation Analysis]
668 Liu C, Xuan LQ, Li K, Feng Z, Lv C, Li XJ, Ji XD, Wan R, Shen J. Shikonin Inhibits Cholangiocarcinoma Cell Line QBC939 by Regulating Apoptosis, Proliferation, and Invasion. Cell Transplant 2021;30:963689720979162. [PMID: 33508949 DOI: 10.1177/0963689720979162] [Reference Citation Analysis]